Document:

1997 Amended and Restated Stock Option Plan

 Exhibit 10.14 
 CHENIERE ENERGY, INC. 
 AMENDED AND RESTATED 
 1997 STOCK OPTION PLAN 
  
 WHEREAS, the Board of Directors (the “Board”) of Cheniere Energy, Inc., a Delaware corporation (the
“Company”), adopted and approved the 1997 Stock Option Plan (the “Original Plan”) on April 22, 1997. By unanimous written consent of the Board, dated October 2, 1997, the Original Plan was amended and
restated effective as of April 22, 1997 and was duly approved by Stockholders on November 5, 1997; and 
  
 WHEREAS, the Original Plan has heretofore been amended to increase the number of shares authorized thereunder and to revise the definition of Fair Market
Value; and 
  
 WHEREAS, the Company desires to incorporate all of
the prior amendments to the Original Plan and the revisions made herein into a restatement of the Original Plan (the Original Plan, as amended and restated hereby, the “Plan”); 
  
 NOW THEREFORE, the Original Plan is hereby amended and restated as follows.
Capitalized words not otherwise defined shall have the meanings set forth below in Article II. 
  
 ARTICLE I 
 PURPOSE 
  
 The Plan is intended to advance the interests of the Company and its stockholders and subsidiaries by attracting, retaining
and motivating the performance of selected directors, officers, consultants and employees of the Company of high caliber and potential upon whose judgment, initiative and effort the Company is largely dependent for the successful conduct of its
business, and to encourage and enable such directors, officers, consultants and employees to acquire and retain a propriety interest in the Company by ownership of its stock. 
  
 ARTICLE II 
 DEFINITIONS 
  
 “Code” means the
Internal Revenue Code of 1986, as amended from time to time, and the rules and regulations thereunder (including Treasury Regulations sec. 1.162-27 and successor regulations thereunder). 
  
 “Committee means the compensation committee appointed by the Board or a sub-committee appointed by the
compensation committee to administer the Plan or, if none, the Board; provided however, that with respect to any Award granted to a Covered Employee which is intended to be “performance-based compensation” as described in
Section 162(m)(4)(c) of the Code, the Committee shall consist solely of two or more “outside directors” as described in Section 162(m)(4)(c)(i) of the Code. 

 Notwithstanding the preceding paragraph, the term “Committee” as used in the Plan with respect
to any Nonqualified Stock Option for a Committee member shall refer to the Board. In the case of a Nonqualified Stock Option for a Committee member, the Board shall have all of the powers and responsibilities of the Committee hereunder as to such
Option, and any actions as to such Options may be acted upon only by the Board (unless it otherwise designates in its discretion). When the Board exercises its authority to act in the capacity as the Committee hereunder with respect to a
Nonqualified Stock Option for a Committee member, it shall so designate with respect to any action that it undertakes in its capacity as the Committee. 
  
 “Common Stock” means the Company’s common stock, $.003 par value per share. 
  
 “Covered Employee” means the Chief Executive Officer of the
Company and each of the four highest paid officers of the Company other than the Chief Executive Officer as described in Section 162(m)(3) of the Code. 
  
 “Date of Grant” means the date on which an Option becomes effective in accordance with Section 6.1 hereof. 
  
 “Effective Date” means April 22, 1997, the date the
Plan was originally adopted by the Board. 
  
 “Eligible
Person” means any person who is a director, officer, consultant or employee of the Company or any Subsidiary. 
  
 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
  
 “Fair Market Value or FMV Per Share” means the closing price of a share of the Common Stock on the
principal exchange or over-the-counter market on which such shares are trading, if any, or as reported on any composite index which includes such principal exchange, as of any given date. If shares of the Common Stock are not listed or admitted to
trading on any exchange, over-the-counter market or any similar organization as of the determination date, the Fair Market Value or FMV Per Share shall be determined by the Committee in good faith using any fair and reasonable means selected in its
discretion. 
  
 “Incentive Stock Option” means a
stock option granted under the Plan that is intended to meet the requirements of Section 422 of the Code. 
  
 “Insider” means an individual who is, on the relevant date, an officer or director designated by the Board to file reports pursuant to
Section 16 of the Exchange Act, with the Securities and Exchange Commission or ten percent (10%) beneficial owner of any class of the Company’s equity securities that is registered pursuant to Section 12 of the Exchange Act, all
as defined under Section 16 of the Exchange Act. 
  
 “Nonqualified Stock Option” means a stock option granted under the Plan that is not an Incentive Stock Option. 
  

 2 

 “Option” means an Incentive Stock Option or a Nonqualified Stock option granted under
the Plan. 
  
 “Optionee” means an Eligible Person
to whom an Option has been granted, which Option has not expired, under the Plan. 
  
 “Option Price” means the price at which each share of Common Stock subject to an Option may by purchased, determined in accordance with Section 6.2 hereof. 
  
 “Performance-Based Exception” means the performance-based
exception from the tax deductibility limitations of Section 162(m) of the Code. 
  
 “Stock Option Agreement” means an agreement between the Company and an Optionee under which the Optionee may purchase Common Stock under the Plan. 
  
 “Subsidiary” means a subsidiary corporation of the Company,
within the meaning of Section 424(f) of the Code. 
  
 ARTICLE III 
 ELIGIBILITY 
  
 All Eligible Persons are eligible to receive a grant of an Option under the Plan. The Committee shall, in its sole discretion, determine and designate
from time to time those Eligible Persons who are to be granted an Option. 
  
 ARTICLE IV 
 ADMINISTRATION 
  
 4.1 Committee Members. The Plan shall be administered by the Committee. 
  
 4.2 Committee Authority. Subject to the express provisions of the
Plan, the Committee shall have the authority, in its discretion, to determine the Eligible Persons to whom an Option shall be granted, the time or times at which an Option shall be granted, the number of shares of Common Stock subject to each
Option, the Option Price of the shares subject to each Option, and the time or times when each Option shall become exercisable and the duration of the exercise period. 
  
 Subject to the express provisions of the Plan, the Committee shall also have discretionary authority to interpret the Plan,
to prescribe, amend and rescind rules and regulations relating to it, to determine the details and provisions of each Stock Option Agreement, and to make all the determinations necessary or advisable in the administration of the Plan. All such
actions and determinations by the Committee shall be conclusively binding for all purposes and upon all persons. No Committee member shall be liable for any action or determination made in good faith with respect to the Plan, any Option or any Stock
Option Agreement entered into hereunder. 
  

 3 

 The Board or the Committee may, by a resolution adopted by the Board or the Committee, authorize one or
more officers of the Company to determine the Eligible Persons to whom an Option shall be granted, the time or times at which an Option shall be granted, the number of shares of Common Stock subject to each Option, the Option Price of the shares
subject to each Option, and the time or times when each Option shall become exercisable and the duration of the exercise period; provided, however, that the resolution so authorizing such officer or officers shall specify the total aggregate number
of Options such officer or officers may award. The Board or the Committee may not authorize an officer to designate himself or herself as a recipient of any Options. 
  
 4.3 Majority Rule. A majority of the members of the Committee (or, if less than three, all of the members) shall
constitute a quorum, and any action taken by a majority present at a meeting at which a quorum is present or any action taken without a meeting evidenced by a writing executed by a majority of the whole Committee shall constitute the action of the
Committee. 
  
 4.4 Company Assistance. The Company shall
supply full and timely information to the Committee on all matters relating to Eligible Persons, their employment or other service to the Company, their death, disability or other termination of service, and such other pertinent facts as the
Committee may require. The Company shall furnish the Committee with such clerical and other assistance as is necessary in the performance of its duties. 
  
 ARTICLE V 
 SHARES OF STOCK SUBJECT TO
PLAN 
  
 5.1 Number of Shares. Subject to adjustment
pursuant to the provisions of Section 5.2 hereof, the maximum number of shares of Common Stock which may be issued and sold hereunder shall be 5,000,000 shares. Shares of Common Stock issued and sold under the Plan may be either authorized but
unissued shares or Shares held in the Company’s treasury. Shares of Common Stock covered by an Option that shall have been exercised shall not again be available for an option grant. If an Option shall terminate for any reason (including,
without limitation, the cancellation of an Option pursuant to Section 6.6 hereof) without being wholly exercised, the number of shares to which such Option termination relates shall again be available for grant hereunder. Unless and until the
Committee determines that a particular Option granted to a Covered Employee is not intended to comply with the Performance-Based Exception, the following rules shall apply to grants of Options to Covered Employees: 
  
 (a) Subject to adjustment as provided in Section 5.2, the maximum
aggregate number of Options for shares of Common Stock that may be granted in any calendar year to any Covered Employee shall be one million (1,000,000) shares. 
  
 (b) With respect to any Option granted to a Covered Employee that is canceled or repriced, the number of shares of Common
Stock subject to such Option shall continue to count against the maximum number of shares that may be the subject of Options granted to such Covered Employees under subsection (a) above and, in this regard, such maximum shall be determined in
accordance with Section 162(m) of the Code. 
  

 4 

 (c) The limitations of subsections (a) and (b) above shall be construed and administered so as
to comply with the Performance-Based Exception. 
  
 5.2
Antidilution. Subject to Article IX hereof, in the event of a reorganization recapitalization, stock split, stock dividend, combination of shares, merger or consolidation, or the sale, conveyance, or other transfer by the Company of all or
substantially all of its property, or any other change in the corporate structure or shares of the Company, pursuant to any of which events the then outstanding shares of Common Stock are split up or combined, or are changed into, become
exchangeable at the holder’s election for or entitle the holder thereof to, other shares of stock, or in the case of any other transaction described in Section 424(a) of the Code, the Committee may change the number and kind of shares
(including by substitution of shares of another corporation) subject to the Options and/or the Option Price of such shares in the manner that it shall deem to be equitable and appropriate. In no event may any such change be made to an Incentive
Stock Option which would constitute a “modification” within the meaning of Section 424(h)(3) of the Code. 
  
 ARTICLE VI 
 OPTIONS 

 
 6.1 Grant of Option. An Option may be granted to any Eligible
Person selected by the Committee. The grant of an Option shall first be effective upon the date it is approved by the Committee, except to the extent the Committee shall specify a later date upon which the grant of an Option shall first be
effective. Each Option shall be designated, at the discretion of the Committee, as an Incentive Stock Option or a Nonqualified Stock Option, provided that Incentive Stock Options may only be granted to Eligible Persons who are considered employees
of the Company or any Subsidiary for purposes of Section 422 of the Code. The Company and the Optionee shall execute a Stock Option Agreement which shall set forth such terms and conditions of the Option as may be determined by the Committee to
be consistent with the Plan, and which may include additional provisions and restrictions that are not inconsistent with the Plan. 
  
 6.2 Option Price. The Option Price shall be determined by the Committee; provided, however, the Option Price of an Incentive Stock Option shall not
be less than 100 percent (100%) of the Fair Market Value of Common Stock on the Date of Grant. To the extent that a Nonqualified Stock Option is intended to qualify for the Performance-Based Exception, the Option Price shall not be less than
100 percent (100%) of the Fair Market Value of Common Stock on the Date of Grant. 
  
 No employee shall be eligible for the grant of any Incentive Stock Option who owns, or would own immediately before the grant of such Incentive Stock Option, directly or indirectly, stock possessing more than ten
percent (10%) of the total combined voting power of all classes 
  

 5 

 of stock of the Company, or any parent or Subsidiary of the Company. This restriction does not apply if, at the time such
Incentive Stock Option is granted, the Option Price is at least one hundred ten percent (110%) of the Fair Market Value on the date of grant and the Incentive Stock Option by its terms is not exercisable after the expiration of five
(5) years from the Date of Grant. For the purpose of the immediately preceding sentence, the attribution rules of Section 424(d) of the Code shall apply for the purpose of determining an employee’s percentage ownership in the Company
or any parent or Subsidiary. This paragraph shall be construed consistent with the requirements of Section 422 of the Code. 
  
 6.3 Vesting; Term of Option. Unless otherwise specified by the Committee in the Stock Option Agreement for an Optionee, an option shall vest and
become exercisable in cumulative annual installments, each of which shall relate to one quarter of the number of shares of Common Stock originally covered thereby (adjusted in accordance with Section 5.2 hereof), on the second, third, fourth
and fifth anniversaries of the Date of Grant, respectively, provided that the Optionee is an Eligible Person on such anniversary. Notwithstanding the foregoing, the Committee, in its sole discretion, may accelerate the exercisability to the extent
provided in Article VIII hereof; provided, however, that no Option may be accelerated or cash paid in lieu of shares if the Committee determines that such action would cause the Optionee to be subject to an excise tax under Section 409A of the
Code. The period during which a vested Option may be exercised shall be ten years from the Date of Grant, unless a shorter exercise period is specified by the Committee in the Stock Option Agreement for any Optionee. 
  
 6.4 Option Exercise; Withholding. An Option may be exercised in whole
or in part at any time, with respect to whole shares only, within the period permitted for the exercise thereof, and shall be exercised by written notice of intent to exercise the Option with respect to a specified number of shares delivered to the
Company at its principal office, and payment in full to the Company at said office of the amount of the Option Price for the number of shares of the Common Stock with respect to which the Option is then being exercised. Payment of the Option Price
shall be made (i) in cash or by cash equivalent, (ii) at the discretion of the Committee, in Common Stock (not subject to limitations on transfer) or (iii) at the discretion of the Committee, by a combination of such cash and such
Common Stock. In addition to and at the time or payment of the Option Price, the Optionee shall pay to the Company in cash or, at the discretion of the Committee, in Common Stock the full amount of all federal and state withholding and other
employment taxes applicable to the taxable income of such Optionee resulting from such exercise. 
  
 6.5 Nontransferability of Option. No option shall be transferred by an Optionee other than by (a) will or the laws of descent and distribution
or (b) pursuant to a domestic relations order. No transfer of an option by the Optionee by will or by laws of descent and distribution shall be effective to bind the Company unless the Company shall have been furnished with written notice
thereof and an authenticated copy of the will and/or such other evidence as the Committee may deem necessary to establish the validity of the transfer. During the lifetime of an Optionee, the Option shall be exercisable only by the Optionee, except
that, in the case of an Optionee who is legally incapacitated, the Option shall be exercisable by his guardian or legal representative. 
  

 6 

 6.6 Cancellation, Substitution and Amendment of Options. The Committee shall have the authority to
effect, at any time and from time to time, with the consent of the affected Optionees, (i) the cancellation of any or all outstanding Options and the grant in substitution therefor of new Options covering the same or different numbers of shares
of Common Stock and having an Option Price which may be the same as or different than the Option Price of the canceled Options or (ii) the amendment of the terms of any and all outstanding Options provided, however, that the Committee shall
have no discretion to exchange, cancel or issue such Options if the exercise of such discretion would cause such Options to be subject to Section 409A of the Code. 
  
 ARTICLE VII 
 INCENTIVE STOCK OPTIONS 
  
 7.1 Annual
Limits. No Incentive Stock Option shall be granted to an Optionee as a result of which the aggregate Fair Market Value (determined as of the Date of Grant) of the stock with respect to which Incentive Stock Options are exercisable for the first
time in any calendar year under the Plan (and any other stock option plans of the Company, any Subsidiary or any parent corporation) would exceed $100,000, as determined in accordance with Section 422(d) of the Code. This limitation shall be
applied by taking Options into account in the order in which granted. 
  
 Notwithstanding any contrary provision in the Plan, to the extent that the aggregate Fair Market Value (determined as of the Date of Grant) of the shares of Common Stock with respect to which Incentive Stock Options are exercisable for the
first time by any Optionee during any single calendar year (under the Plan and any other stock option plans of the Company and its Subsidiaries or parent) exceeds the sum of $100,000, such Incentive Stock Option shall be treated as a Nonqualified
Stock Option and not as an Incentive Stock Option, but all other terms and provisions of such Stock option shall remain unchanged. This paragraph shall be applied by taking Incentive Stock Options into account in the order in which they are granted.

  
 7.2 Disqualifying Dispositions. If shares of Common
Stock acquired by exercise of an Incentive Stock Option are disposed of within two years following the Date of Grant or one year following the transfer of such shares to the Optionee upon exercise, the Optionee shall, within 10 days after such
disposition, notify the Company in writing of the date and terms of such disposition and provide such other information regarding the disposition as the Committee may reasonably require. With respect to any disqualifying disposition of shares of
Common Stock received by an Optionee pursuant to the exercise of an Incentive Stock Option, the Company shall have the right to withhold from any salary, wages or other compensation payable by the Company to the Optionee an amount sufficient to
satisfy federal, state and local tax withholding requirements attributable to such disqualifying disposition. 
  
 7.3 Other Terms and Conditions. Any Incentive Stock Option granted hereunder shall contain such additional terms and conditions, not inconsistent
with the terms of this Plan, as are deemed necessary, or desirable by the Committee, which terms, together with the terms of this Plan, shall be intended and interpreted to cause such Incentive Stock Option to qualify as an “incentive stock
option” under Section 422 of the Code. 
  

 7 

 ARTICLE VIII 
 TERMINATION OF SERVICE 
  
 8.1 Death. Except if otherwise provided in the Stock Option Agreement, if an Optionee shall die at any time after the Date of Grant and while he is an Eligible Person, the executor or administrator of the estate of the decedent, or
the person or persons to whom an Option shall have been validly transferred in accordance with Section 6.5 hereof pursuant to will or the laws of descent and distribution, shall have the right, during the period ending one year after the date
of the Optionee’s death (subject to Section 6.3 hereof concerning the maximum term of an Option), to exercise the Optionee’s Option to the extent that it was exercisable at the date of the Optionee’s death and shall not have been
previously exercised. The Committee may determine at or after the Date of Grant to make any portion of the Optionee’s Option that is not exercisable at the date of death immediately vested and exercisable. No Incentive Stock Option may be
exercised more than one year after the Optionee’s termination of employment due to death. 
  
 8.2 Disability. Except if otherwise provided in the Stock Option Agreement, if an Optionee’s employment or other service with the Company or any Subsidiary shall be terminated as a result of his permanent
and total disability (within the meaning of Section 22(e)(3) of the Code) at any time after the Date of Grant and while he is an Eligible Person, the Optionee (or in case of an Optionee who is legally incapacitated, his guardian or legal
representative) shall have the right, during a period ending one year after the date of his termination due to disability (subject to Section 6.3 hereof concerning the maximum term of an Option), to exercise such Option to the extent that it
was exercisable at the date of such termination of employment or other service and shall not have been exercised. The Committee may determine at or after grant to make any portion of this Option that is not exercisable at the date of termination of
employment or other service due to disability immediately vested and exercisable. No Incentive Stock Option may be exercised more than one year after the Optionee’s termination of employment due to disability. 
  
 8.3 Termination for Cause. If an Optionee’s employment or other
service with the Company or any Subsidiary shall be terminated for cause, the Optionee’s right to exercise any unexercised portion of this Option shall immediately terminate and all rights thereunder shall cease. For purposes of this
Section 8.3, termination for “cause” shall include, but not be limited to, embezzlement or misappropriation of funds, any acts of dishonesty resulting in conviction for a felony, misconduct resulting in material injury to the Company
or any Subsidiary, significant activities harmful to the reputation of the Company or any Subsidiary, a significant violation of Company or Subsidiary policy, willful refusal to perform, or substantial disregard of, the duties property assigned to
the Optionee, or a significant violation of any contractual statutory or common law duty of loyalty to the Company or any Subsidiary. The Committee shall have the power to determine whether the Optionee has been terminated for cause and the date
upon which such termination for cause occurs. Any such determination shall be final, conclusive and binding upon the Optionee. 
  

 8 

 8.4 Other Termination of Service. Except if otherwise provided in the Stock Option Agreement, if
an Optionee’s employment or other service with the Company or any Subsidiary shall be terminated for any reason other than death, permanent and total disability or termination for cause, the Optionee shall have the right, during the period
ending 90 days after such termination (subject to Section 6.3 hereof concerning the maximum term of an Option), to exercise such Option to the extent that it was exercisable at the date of such termination and shall not have been exercised. For
purposes of this Section 8.4, an Optionee shall not be considered to have terminated employment or other service with the Company or any Subsidiary until the expiration of the period of any military, sick leave or other bona fide leave of
absence, up to a maximum period of 90 days (or such greater period during which the Optionee is guaranteed reemployment either by statute or contact). 
  
 ARTICLE IX 
 CHANGE IN CONTROL

  
 9.1 Change in Control. Upon a “change in
control” of the Company (as defined in Section 9.2), each outstanding Option, to the extent that it shall not otherwise have become vested, shall become fully and immediately vested (without regard to any otherwise applicable vesting
requirement under Section 6.3 or in the Stock Option Agreement) and an Optionee shall surrender his option and receive with respect to each share of Common Stock issuable under such Option outstanding at such time, a payment is cash equal to
the excess of the Fair Mark Value of the Common Stock at the time of the change in control over the Option Price of the Common Stock; provided, however, that no such vesting and cash payment shall occur if (i) the change in control has been
approved by at least two-thirds of the members of the Board who were serving as such immediately prior to such transaction and (ii) provision has been made in connection with such transaction for (a) the continuation of the Plan and/or the
assumption of such Options by a successor corporation (or a parent or subsidiary thereof) or (b) the substitution for such Options of new options covering the stock of a successor corporation (or a parent or subsidiary thereof), with
appropriate adjustments as to the number and kinds of shares and exercise prices. In the event of any such continuation, assumption or substitution, the Plan and/or such Options shall continue in the manner and under the terms so provided.

  
 9.2 Definition. For purposes of Section 9.1
hereof, a “change in control” of the Company shall mean: 
  
 (a) The acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act (a “Person”) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the
Exchange Act) of fifty percent (50%) or more of the total voting power of all of the Company’s then outstanding securities entitled to vote generally in the election of directors to the Board; provided, however, that for purposes of this
subsection (a), the following acquisitions shall not constitute a change in control; (i) any acquisition by the Company or its parent or Subsidiaries, (ii) any acquisition by any employee benefit plan (or related trust) sponsored or
maintained by the Company or its parent or Subsidiaries, or (iii) any acquisition consummated with the prior approval of the Board; or 
  

 9 

 (b) During the period of two consecutive calendar years, individuals who at the beginning of such period
constitute the Board, and any new director(s) whose (i) election by the Board or (ii) nomination for election by the Company’s shareholders, was approved by a vote of at least two-thirds of the directors then still in office who
either were directors at the beginning of the two-year period or whose election or nomination for election was previously so approved, should cease for any reason to constitute a majority of the Board; or 
  
 (c) The Company becomes a party to a merger, plan of reorganization,
consolidation or share exchange in which either (i) the Company will not be the surviving corporation or (ii) the Company will be the surviving corporation and any outstanding shares of the Company’s common stock will be converted
into shares of any other company (other than a reincorporation or the establishment of a holding company involving no change of ownership of the Company) or other securities, cash or other property (excluding payments made solely for fractional
shares); or 
  
 (d) The shareholders of the Company approve a
merger, plan of reorganization, consolidation or share exchange with any other corporation, and immediately following such merger, plan of reorganization, consolidation or share exchange the holders of the voting securities of the Company
outstanding immediately prior thereto hold securities representing fifty percent (50%) or less of the combined voting power of the voting securities of the Company or such surviving entity outstanding immediately after such merger, plan of
reorganization, consolidation or share exchange; provided, however, that notwithstanding the foregoing, no change in control shall be deemed to have occurred if one-half (1/2) or more of the members of the Board of the Company or such surviving
entity immediately after such merger, plan of reorganization, consolidation or share exchange is comprised of persons who served as directors of the Company immediately prior to such merger, plan of reorganization, consolidation or share exchange or
who are otherwise designees of the Company; or 
  
 (e) Upon
approval by the Company’s stockholders of a complete liquidation and dissolution of the Company or the sale or other disposition of all or substantially all of the assets of the Company other than to a parent or Subsidiary; or 
  
 (f) Any other event that a majority of the Board, in its sole discretion,
shall determine constitutes a change in control for purposes of Section 9.1. 
  
 Notwithstanding the occurrence of any of the foregoing events of this Section 9.2 which would otherwise result in a change in control, the Board may determine in its sole discretion, if it deems it to be in the
best interest of the Company, that an event or events otherwise constituting a change in control shall not be considered a change in control. Such determination shall be effective only if it is made by the Board as it is constituted prior to the
occurrence of an event that otherwise would be or probably would lead to a change in control; or after such event if made by the Board a majority of which is composed of directors who were members of the Board immediately prior to the event that
otherwise would be or probably would lead to a change in control. 
  
 9.3 Exchange of Options. The Committee may, in its discretion, permit any Optionee to surrender outstanding Options in order to exercise or realize his rights under other Options or in exchange for the grant of new Options, or
require holders of Options to surrender outstanding Options as a condition precedent to the grant of new Options. 
  

 10 

 ARTICLE X 
 STOCK CERTIFICATES 
  
 10.1 Issuance of Certificates. Subject to Section 10.2 hereof, the Company shall issue a stock certificate in the name of the Optionee (or other person exercising the option in accordance with the provisions of the Plan) for the
shares of Common Stock purchased by exercise of an option as soon as practicable after due exercise and payment of the aggregate Option Price for such shares. A separate stock certificate or separate stock certificates shall be issued for any shares
of Common Stock purchased pursuant to the exercise of an Option that is an Incentive Stock Option, which certificate or certificates shall not include any shares of Common Stock that were purchased pursuant to the exercise of an Option that is a
Nonqualified Stock Option. 
  
 10.2 Conditions. The Company
shall not be required to issue or deliver any certificate for shares of Common Stock purchased upon the exercise of any Option granted hereunder or any portion thereof prior to fulfillment of all of the following conditions: 
  
 (a) The completion of any registration or other qualification of such
shares, under any federal or state law or under the rulings or regulations of the Securities and Exchange Commission or any other governmental regulatory body, that the Committee shall in its sole discretion deem necessary or advisable; 

 
 (b) The obtaining of any approval or other clearance from any federal or
state governmental agency which the Committee shall in its sole discretion determine to be necessary or advisable; 
  
 (c) The lapse of such reasonable period of time following the exercise of the Option as the Committee from time to time may establish for reasons of
administrative convenience; 
  
 (d) Satisfaction by the Optionee
of all applicable withholding taxes or other withholding liabilities; and 
  
 (e) If required by the Committee, in its sole discretion, the receipt by the Company from an Optionee of (i) a representation in writing that the shares of Common Stock received upon exercise of an Option are
being acquired for investment and not with a view to distribution and (ii) such other representations and warranties as are deemed necessary by counsel to the Company. 
  
 10.3 Legends. The Company reserves the right to legend any certificate for shares of Common Stock, conditioning sales
of such shares upon compliance with applicable federal and state securities laws and regulations. 
  

 11 

 ARTICLE XI 
 TERMINATION AND AMENDMENT 
  
 11.1 Termination and Amendment. The Plan shall terminate on April 22, 2007. Notwithstanding the foregoing, the Board shall have complete power and authority to terminate the Plan at an earlier date or to amend the Plan;
provided, however, the Board shall not, without the approval of the stockholders of the Company within the time period required by applicable law, (a) increase the maximum number of shares which may be issued under the Plan pursuant to
Section 5.1, (b) amend the requirements as to the class of employees eligible to receive Options for Common Stock under the Plan, (c) extend the term of the Plan, or (d) decrease the authority granted to the Committee under the
Plan in contravention of (i) Rule 16b-3 under the Exchange Act or (ii) Section 162(m) of the Code to the extent that the Committee seeks compliance with Section 162(m). No termination or amendment of the Plan shall adversely
affect the rights of an Optionee (or his permitted transferee) under a previously granted or transferred Option without his written consent. 
  
 In addition, to the extent that the Committee determines that (a) the listing for qualification requirements of any national securities exchange or
quotation system on which the Common Stock is then listed or quoted, or (b) the Code (or regulations promulgated thereunder), require stockholder approval in order to maintain compliance with such listing requirements or to maintain any
favorable tax advantages or qualifications, then the Plan shall not be amended in such respect without obtaining the approval of the Company’s stockholders within the prescribed time period. 
  
 With respect to insiders, transactions under the Plan are intended to comply
with all applicable conditions of Rule 16b-3 under the Exchange Act. Any ambiguities or inconsistencies in the construction of any Stock Option Agreement or the Plan shall be interpreted to give effect to such intention. 
  
 Unless otherwise determined by the Committee with respect to any particular
Option grant, it is intended that the Plan comply fully with and meet all the requirements of Section 162(m) of the Code so that any Stock Options that are granted to Covered Employees shall qualify for the Performance-Based Exception. If any
provision of the Plan or a Stock Option Agreement would not permit the Plan or Stock Option to comply with the Performance-Based Exception as so intended, such provision shall be construed or deemed amended to conform to the requirements of the
Performance-Based Exception to the extent permitted by applicable law and deemed advisable by the Committee; provided, however, no such construction or amendment shall have an adverse effect on the prior grant of any Stock Option or on the economic
value to an Optionee (or his permitted transferee) of any outstanding Stock Option. 
  
 ARTICLE XII 
 MISCELLANEOUS 
  
 12.1 Employment or other Service. Nothing in the Plan, in the grant of any Option or in any Stock Option Agreement
shall confer upon any Eligible Person the right to continue in the 
  

 12 

 capacity in which he is employed by or otherwise provides services to the Company or any Subsidiary. Notwithstanding
anything contained in the Plan to the contrary, unless otherwise provided in a Stock Option Agreement, no Option shall be affected by any change of duties or position of the Optionee (including a transfer to or from the Company or any Subsidiary),
so long as such Optionee continues to be an Eligible Person. 
  
 12.2 Rights as Shareholder. An Optionee or the permitted transferee of an option shall have no rights as a shareholder with respect to any shares subject to such Option prior to the purchase of such shares by exercise of such Option
as provided herein. Nothing contained herein or in the Stock Option Agreement relating to any Option shall create an obligation on the part of the Company to repurchase any shares of Common Stock purchased hereunder. 
  
 12.3 Compensation and Benefit Plans. The adoption of the Plan shall
not affect any other stock option or incentive or other compensation plans in effect for the Company or any Subsidiary, nor shall the Plan preclude the Company from establishing any other forms of incentive or other compensation for employees of the
Company or any Subsidiary. The amount of any compensation deemed to be received by an Optionee as a result of the exercise of an Option or the sale of shares received upon such exercise shall not constitute compensation with respect to which any
other employee benefits of such Optionee are determined, including, without limitation, benefits under any bonus, pension, profit sharing, life insurance or salary continuation plan, except as otherwise specifically determined by the Board or the
Committee or provided by the terms of such plan. 
  
 12.4 Plan
Binding on Successors. The Plan shall be binding upon the Company, its successors and assigns, and the Optionee, his executor, administrator and permitted transferees. 
  
 12.5 Construction and Interpretation. Whenever used herein, nouns in the singular shall include the plural, and the
masculine pronoun shall include the feminine gender. Headings of Articles and Sections hereof are inserted for convenience and reference and constitute no part of the Plan. 
  
 12.6 Severability. If any provision of the Plan or any Stock Option Agreement shall be determined to be illegal or
unenforceable by any court of law in any jurisdiction, the remaining provisions hereof and thereof shall be severable and enforceable in accordance with their terms, and all provisions shall remain enforceable in any other jurisdiction. 

 
 12.7 Governing Law. The validity and construction of this Plan and
of the Stock Option Agreements shall be governed by the laws of the State of Texas, without regard to its conflicts of law provisions. 
  

 13License Agreement

 Exhibit 10.1 
  
 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Securities and Exchange
Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  
 LICENSE AGREEMENT 
  
 This License Agreement, effective as of September 20, 2005 (the “Effective Date”), is made by and between STANDARD & POOR’S
(“S&P”), a division of The McGraw-Hill Companies, Inc., a New York corporation having an office at 55 Water Street, New York, New York 10041, and the CHICAGO MERCANTILE EXCHANGE Inc. (“CME”), a Delaware corporation having an
office at 20 South Wacker Drive, Chicago, Illinois 60606. 
  
 RECITALS: 
  
 WHEREAS, S&P
compiles, calculates, maintains and owns rights in and to the various stock indices listed in Appendix 1 to this Agreement and to the proprietary data contained therein; and 
  
 WHEREAS, the S&P Stock Indices include the S&P 500/CITIGROUP Growth Index and the S&P 500/CITIGROUP Value
Index which S&P and CITIGROUP, Inc. (“CITIGROUP”) together compile, calculate, maintain and own rights in; and 
  
 WHEREAS, S&P uses in commerce and has trade name and trademark rights to the designations listed in Appendix 2 to this Agreement, including the
designations “S&P 500/CITIGROUP Growth Index” and “S&P 500/CITIGROUP Value Index” which S&P uses with CITIGROUP’s permission; and 
  
 WHEREAS, CME wishes to use the S&P Stock Indices and S&P Marks in connection with: (1) creating,
issuing, listing, trading, clearing, marketing, and promoting Futures Contracts and Options on Futures Contracts and activities related thereto; and (2) making disclosure about such Contracts under applicable laws, rules and regulations in
order to identify that S&P is the source of the S&P Stock Indices, pursuant to the terms and conditions hereinafter set forth; and 
  
 WHEREAS, S&P wishes to license CME to use the S&P Stock Indices and the S&P Marks for the purposes stated above and wishes, and has the
right (with CITIGROUP’s consent), to license the S&P/CITIGROUP Indices and S&P/CITIGROUP Marks to third parties, such as CME; and 
  
 WHEREAS, the current license relationship between CME and S&P is set forth in a license agreement dated September 24, 1997, as amended
(the “1997 Agreement”); and 
  
 WHEREAS, the
parties wish to (i) modify and extend their license relationship on the terms and conditions set forth herein, and (ii) supersede and replace all prior agreements with regard to the subject matter of this License Agreement; 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements
contained herein, it is agreed as follows: 
  

	1.	DEFINITIONS. For purposes of this License Agreement, the following definitions shall apply: 

  
 (a) “Agreement” shall mean this License Agreement. 
  
 (b) “CFTC” shall mean the Commodity Futures Trading Commission, as
from time to time constituted or, if at any time after the execution of this Agreement such Commission is not existing and performing the duties assigned to it under the Commodity Exchange Act, as amended, then the body performing such duties at
such time. 
  
 (c) “CME Substitute Contracts” shall have
the meaning ascribed in Section 8 of this Agreement. 
  
 (d)
“CME Substitute Index” shall have the meaning ascribed in Section 8 of this Agreement. 
  
 (e) “Competitive Contract” shall mean a Contract based upon a Competitive Index. 
  
 (f) “Competitive Index” shall mean the ***** or any index other than an index for which CME pays S&P a license
fee: (1) in which ***** or more of the ***** are also ***** of an S&P Index that is licensed to CME on an exclusive basis, and which has ***** to such S&P Index for the ***** period immediately prior to the Launch Date and each Launch
Anniversary Date, as applicable; and (2) the ***** of which include ***** or more of the ***** of an S&P Stock Index that is licensed to CME on an exclusive basis, and which has ***** to such S&P Index for the ***** period prior to the
Launch Date and each Launch Anniversary Date, as applicable. 
  
 (g) “Competitive Market” shall mean (1) an organized, regulated derivatives market that is subject to regulation as a designated contract market regulated by the CFTC or under a comparable international regulatory structure
that employs a central counter-party model offers for trading products that would be Futures Contracts under this Agreement (for example, without limitation, CBOT, CBOE, Eurex, Euronext-Liffe, SGX, Tokyo Stock Exchange, Korea Exchange) or
(2) an entity that offers electronic trading in futures look-alike products (meaning highly-standardized products for future settlement or delivery) and that has obtained a recognized status or formal exemptive or no-action relief from the CFTC
in order to offer such products for trading to U.S. customers. 
  
 (h) “Confidential Information” shall have the meaning ascribed to it in Section 12(b) of this Agreement. 
  
 (i) “Contract” shall mean a Futures Contract or Option Contract that utilizes a single S&P Stock Index hereunder. 
  

 Page 2 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 (j) “Emerging Indices” shall include indices that are not based on developed indices.
Emerging Indices include but are not limited to: 1. indices based on geographically emerging markets (a “China” index or a “Middle East” index); 2. indices that are constructed in novel or unique ways that are unfamiliar to most
market participants (for example, a new index construction that relies on the prices of intervening instruments might be an emerging index, especially if there are no commonly-traded products using the index at the time it is offered to CME); and 3.
indices based on underlying products that have not developed liquid trading in the direct market for the products of which the index is composed (for example, an index composed of prices of new and illiquid ETFs). 
  
 (k) “ETF” shall mean: a pooled investment vehicle, trust,
investment company or other collective or commingled investment vehicle (including, but not limited to, an issuer registered under the U.S. Investment Company Act of 1940), that has the following characteristics: (i) the ETF issues, sells, and
redeems blocks of shares or other interests, which blocks are sometimes referred to as “creation units”; (ii) the shares, units or similar interests thereof are listed on an exchange; and (iii) the investment objective thereof is
to own a basket of stocks and/or other financial instruments (such as futures, options, and other derivative contracts) in an attempt to replicate substantially the price and dividend performance of the stocks represented by a single index, such as
an S&P Stock Index. 
  
 (l) “Futures Contracts”
shall mean: (1) all instruments: (A) the trading of which is within the exclusive jurisdiction of CFTC (assuming for this purpose that the instruments were traded in the United States regardless of where they are actually traded),
(B) which are regulated by the CFTC as futures contracts (assuming for this purpose that such instruments were traded in the United States regardless of where they are actually traded), and (C) which CME has the authority to trade under
its articles, by-laws, and rules; and (2) those instruments which, as of September 24, 1997, meet all of the requirements specified in clause (1) of this Subsection (l) but subsequent to September 24, 1997 fail to meet the
requirements of clause (1)(A) of this Subsection (l) solely because another U.S. regulatory authority (in addition to, or in substitution of, the CFTC) is given regulatory jurisdiction over such instruments. 
  
 (m) “Indexed Contracts” shall mean (1) Futures Contracts the
final settlement price of which is calculated using one or more values of an S&P Stock Index and (2) Option Contracts on such Futures Contracts. Indexed Contracts include, without limitation, S&P ETF Contracts. 
  
 (n) “Launch Date” shall mean the first day that a Contract begins
trading on the CME. 
  
 (o) “Launch Anniversary Date”
shall mean each ***** anniversary of a Launch Date. 
  
 (p)
“Normalized Volume” shall be calculated by applying the formula specified in item 3 of Appendix 6 attached hereto. 
  
 (q) “Notional Value” of a Contract shall mean (a) where the final settlement value of such Contract uses the level of an S&P Stock
Index, the product of the multiplier of such Contract and the closing value of the underlying index on the date of calculation and (b) where the final settlement value of such Contract uses the price of an S&P Index ETF share, the product
of the 

  

 Page 3 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 
number of such S&P Index ETF shares included in such Contract and the price of such S&P Index ETF share on the date of calculation. 
  
 (r) “Option Contract” shall mean an option to purchase or sell
Futures Contracts. An Option Contract shall not include a contract that satisfies both of the following criteria: (i) it was a security under the Securities Exchange Act of 1934, as amended as of December 1, 1990, and (ii) it was not
an option on a future under the Commodities Exchange Act, as amended as of December 1, 1990. 
  
 (s) “S&P Affected Contract” shall have the meaning set forth in Section 5(g). 
  
 (t) “S&P/CITIGROUP Indices” shall mean the S&P
500/CITIGROUP Growth Index and the S&P 500/CITIGROUP Value Index. 
  
 (u) “S&P/CITIGROUP Marks” shall mean the designations “S&P 500/CITIGROUP Growth Index” and “S&P 500/CITIGROUP Value Index.” 
  
 (v) “S&P ETF Contracts” shall mean all Futures Contracts and Option Contracts on such Futures Contracts, that
use an S&P Index ETF as their sole underlying interest and that were under the joint jurisdiction of the SEC and CFTC as of February 18, 2005, including any such contract that is a security future as such term is currently defined in
Section 1a(31) of the Commodity Exchange Act (CEA). 
  
 (w)
“S&P Index ETF” means an ETF as to which the sole underlying index is an S&P Stock Index. 
  
 (x) “S&P Marks” shall mean the designations listed in Appendix 2 to this Agreement. 
  
 (y) “S&P Stock Indices” shall mean the stock indices listed in
Appendix 1 to this Agreement. 
  
 (z) “Sector-based
Indices” shall include indices that are target to a specific business sector. Sector-based Indices include but are not limited to: S&P Energy Stock Price Index, S&P Financial Stock Price Index, S&P High Technology Stock Price Index,
S&P Public Utility Stock Price Index, S&P Consumer Staple Stock Price Index, S&P Transportation Stock Price Index, S&P Energy Stock Price Index, S&P Financial Stock Price Index, S&P High Technology Stock Price Index, S&P
High Technology Stock Price Index, S&P Public Utility Stock Price Index, S&P Public Utility Stock Price Index, S&P Consumer Staple Stock Price Index, S&P Consumer Staple Stock Price Index, S&P Transportation Stock Index and
S&P Transportation Stock Price Index. 
  
 (z) “Total
Volume” shall mean the total volume of all Indexed Contracts that utilize the S&P 500 Index, plus the Total Normalized Volume (as defined in Appendix 6) in the Competitive Contract. 
  

 Page 4 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

	2.	GRANT OF LICENSE. 

  
 (a) General. Subject to the terms and conditions of this Agreement, S&P hereby grants to CME worldwide licenses: (1) to use the S&P
Stock Indices solely in connection with creating, issuing, listing, trading, clearing, marketing, and promoting Indexed Contracts; and (2) to use and refer to the S&P Marks in connection with creating, issuing, listing, trading, clearing,
marketing, and promoting Indexed Contracts and with making such disclosures about Indexed Contracts as CME deems necessary or desirable under any applicable federal or state laws, rules or regulations or under this Agreement in order to indicate the
source of the S&P Stock Indices. 
  
 (b) Electronic Trading
System Rights. The licenses granted to CME by this Agreement extend to the trading of Indexed Contracts at CME and also on any electronic trading system on which CME offers its products for trading, but only to the extent that the Indexed
Contracts traded on such electronic trading system are cleared by CME. 
  
 (c) Index Value Dissemination Rights. Subject to the terms and conditions of this Agreement, S&P further grants to CME a non-exclusive worldwide license to disseminate, at CME’s sole expense, the S&P Stock Indices, in
real-time, internally, via the GLOBEX system and to and through third-party communications vendors, for information purposes, pursuant to and subject to the terms and conditions set forth in Appendix 7. 
  
 (d) Limited Licenses. CME acknowledges that the S&P Stock Indices
(except for the S&P/CITIGROUP Indices) and the S&P Marks (except for the S&P/CITIGROUP Marks) are the exclusive property of S&P, that S&P has and retains all proprietary rights therein (including, but not limited to, trademarks
and copyrights), and that the S&P Stock Indices (except for the S&P/CITIGROUP Indices) and their compilation and composition and changes therein are in the complete control and discretion of S&P. CME acknowledges that the
S&P/CITIGROUP Indices and the S&P/CITIGROUP Marks are the exclusive property of S&P and CITIGROUP, that S&P and CITIGROUP have and retain all proprietary rights therein (including, but not limited to, trademarks and copyrights) and
that the S&P/CITIGROUP Indices and their compilation and composition and changes therein are in the complete control and discretion of S&P and CITIGROUP. Except as otherwise specifically provided herein, S&P reserves all rights to the
S&P Stock Indices and the S&P Marks which are not expressly licensed hereunder and this Agreement shall not be construed to transfer to CME any right to, or interest in, the S&P Stock Indices or the S&P Marks, or in any copyright,
trademark or proprietary right pertaining thereto. 
  
 (e)
Licensing of Additional S&P Stock Indices. Unless otherwise agreed by the parties in writing, this Agreement shall govern any and all licenses to S&P Stock Indices (whether newly created by S&P or resumed after discontinuation)
and S&P Marks granted by S&P to CME during the term of this Agreement. Upon the granting by S&P to CME of any such license, Appendix 1 and 2 to this Agreement shall be amended accordingly. 
  
 (f) Restrictions on Indexed Contracts. Aside from S&P’s
limited approval rights provided below, there will be no restrictions placed on how CME structures Indexed Contracts or how 

  

 Page 5 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 
CME offers Indexed Contracts for trading, except as specifically described below with respect to novel settlement methodology and product construction and
certain other types of Indexed Contracts. For example, CME may structure an Indexed Contract that is a Futures Contract based upon a combination of S&P Stock Indices. CME may also offer separate Indexed Contracts on different S&P Stock
Indices and facilitate spread trading among them through special quoting or pricing mechanisms. For the avoidance of doubt, CME may continue to offer Indexed Contracts for trading through any trading or quoting mechanism that CME offers today,
including quoting based on volatility, without limitation of any trading or quoting mechanisms that CME may offer in the future. CME may offer spread trading that results in multiple Indexed Contracts being traded and CME collecting fees for those
Indexed Contracts and in such event, S&P will be paid license fees for each of those Indexed Contracts as if each Indexed Contract had traded separately. If CME lists a spread product reflecting an interest in multiple Indexed Contracts as a
separate instrument such that one Indexed Contract is traded and CME collects fees for one Indexed Contract, S&P will be paid a license fee for one Indexed Contract at the highest per-Contract rate that would apply to any included Indexed
Contract. 
  
 If an Indexed Contract developed by CME or a third
party uses a novel settlement methodology or novel construction, then: 
  
 (1) to the extent that the ultimate settlement value that uses an S&P Stock Index value (the “S&P Settlement Value”) constitutes protectible intellectual property, S&P shall own the settlement
value, which shall be exclusively licensed to CME under this Agreement, and S&P shall be paid the applicable fee for each trade of such Indexed Contract. 
  

(2) to the extent that the methodology or product construction is CME’s development and constitutes protectible intellectual
property, CME shall own the intellectual property rights in the methodology and product construction. 
  
 (3) nothing in this Agreement shall give CME the right to license a third party to use the S&P Settlement Value in conjunction with
the CME methodology or product construction, nor shall it give S&P the right to license a third party to use the CME methodology or product construction (or the settlement value that results from the use of it). 
  
 (4) CME shall obtain S&P’s prior approval before
launching an Indexed Contract that employs a novel settlement methodology or product construction, which approval may only be withheld if S&P reasonably concludes that the proposed Indexed Contract presents (i) a legal or regulatory risk to
S&P, (ii) a risk of tarnishing S&P’s business reputation by virtue of its presumed association with an Indexed Contract, including where an S&P Index value might be combined with an index value of a competitor to S&P, or
(iii) without limitation of S&P’s right of review under Section 10(a) of this Agreement, a risk to S&P’s rights in the S&P Marks that is caused by CME’s proposed name for the Indexed Contract. In addition, with
respect to any proposed Indexed Contract that is calculated using one or more values of an S&P Stock Index in combination with an index or indices of index providers other than S&P, regardless of whether it constitutes a novel settlement
methodology or product construction, S&P’s 

  

 Page 6 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 
prior approval, subject to the same conditions as set forth in this subsection 2(f)(4), shall be required. 
  
 A settlement methodology or product construction shall be
considered “novel” for purposes of this section if it is a methodology or construction that was not used in any product listed for trading on a global exchange on or before the Effective Date. 
  
 (5) With respect to so-called “TRAKRS” products
that as of the Effective Date trade on CME and that are calculated using one or more values of an S&P Stock Index, the parties acknowledge and agree that, beginning as of the Effective Date, they are Indexed Contracts for purposes of this
Agreement, including without limitation Section 5 hereof. With respect to any new TRAKRS products, or any other product that is an Indexed Contract hereunder that is issued or sponsored by a third party, CME agrees that such third party shall
be required, to the extent required by law, to obtain a license or other authorization from S&P to use the relevant S&P Stock Index and S&P Marks in connection with that product before that product may be listed on CME. 
  
 (g) CBOE-S&P License. Notwithstanding Section 2(f), CME will
not list for trading Indexed Contracts that are exclusively licensed by S&P to CBOE/CFE under Amendment No. 6 to the S&P-CBOE license agreement during the term of that amendment, in that CME shall not use the S&P 500 or S&P 100
Indices to derive, maintain, publish, calculate or disseminate a Volatility Index, Variance Indicator or BuyWrite Index (as defined therein), or the S&P Marks, in connection with the creation, issuance, exercise of an investment product of any
kind or character whatsoever, including without limitation Futures Contracts or Option Contracts. The limitations of this Subsection 2(g) shall not apply if CME is providing services to CBOE or other party duly licensed by S&P with that
party’s consent. CME agrees not to dispute under the 1997 Agreement, and to “grandfather” under this Agreement, the exclusive rights that S&P granted to CBOE relating to the listing of certain futures products that use the S&P
500 index as described in Amendment No. 6 to the S&P-CBOE license provided to CME. In consideration for this, S&P agrees to pay CME *****. CME relinquishes any claim to list Indexed Contracts that use an S&P 500 variance, volatility
or buy-write index to the extent that such products are granted exclusively to CBOE under its S&P license during the term of that license. For the avoidance of doubt, this protection of CBOE’s rights does not limit the pricing or quoting
mechanisms through which CME offers allowed Indexed Contracts for trading, including, without limitation, quoting based on volatility. The rights grandfathered to CBOE are non-transferable. Those rights shall revert to CME upon the expiration or
termination of the grant to CBOE to the extent that those rights are otherwise granted to CME in this Agreement. CME agrees to make no claim that this Agreement grants CME the right to list Indexed Contracts that use CFE’s proprietary indices,
such as the VIX, or any other proprietary indices of a third party. 
  
 (h) S&P ETF Contracts. All S&P ETF Contracts shall be based on an underlying amount of 100 shares of the relevant S&P Index ETF. However, if the value of such share is decreased by 30% or more from its value when the
corresponding S&P ETF Contract was first launched, CME may increase the number of ETF shares in the S&P ETF Contract in order to approximate the original Notional Value of the Contract. Such an increase may be made in 100 share increments or
other increments that in CME’s sole discretion is determined to be the most conducive to trading the S&P ETF Contract even if such an increase makes the value of the S&P ETF Contract greater than the initial value of the S&P ETF
Contract. 
  

 Page 7 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

	3.	EXCLUSIVITY. 

  
 (a) Licensed Indices. Subject to and except as otherwise provided in this Agreement, the license for the S&P Stock Indices listed in Appendix 1
shall be exclusive for the period commencing on the Effective Date and ending on December 31, 2016. The license shall continue on a non-exclusive basis thereafter for the duration of the term of this Agreement. 
  
 (b) S&P 500 Index. (i) For the S&P 500 Index, CME’s
exclusive rights will automatically extend through December 31, 2008. With respect to each subsequent ***** during the license term, CME will retain its exclusive rights to the S&P 500 as long as the E-mini S&P 500 Contract, as
currently structured (i.e., with a multiplier of $50), achieves a total average daily volume (“ADV”) of at least ***** contracts (“E-mini ADV Threshold”). If in any *****, the E-mini ADV Threshold is not achieved, CME will
have the option to continue its exclusivity for the following ***** if CME pays to S&P the difference between the total license fees associated with the trading of the E-mini S&P 500 Contract for the ***** and the total license fees that
would have been paid to S&P if the E-mini ADV Threshold had been exactly met for such *****. If CME does not remit such payment to S&P, CME’s license for the S&P 500 shall become nonexclusive for the remainder of the license term.
S&P shall provide CME written notice following any ***** in which the ADV Threshold is not met or prior to licensing any other party, with a period of at least 45 days for CME to make up any payments and in such case CME would retain the
exclusivity to the S&P 500 Index. Notwithstanding the foregoing, CME shall maintain its exclusivity and not be required to make any additional payments to S&P if the E-mini ADV Threshold is not met and any of the following circumstances
apply and, as applicable, continue to apply: 
  
 (1) the average daily trading volume in S&P 500 equity index options (for purposes of this paragraph options on S&P Index ETFs such as “SPDRs” and “iShares S&P 500” will be considered S&P 500 equity index
options) listed on CBOE and/or any other options exchange has declined by ***** or more from the value reported immediately after the Effective Date; 
  
 (2) The amount of money that is benchmarked to the S&P 500 Index, as reported in S&P’s published Annual Survey of Indexed
Assets, has declined by ***** or more from the value reported immediately after the Effective Date, based on the report published immediately before the end of the ***** in question; or 
  
 (3) The decline in CME’s trading volume can be attributed in substantial part to a change in the
regulatory treatment or tax treatment that applies to CME’s E-mini S&P 500 Contract (for example, without limitation, the loss of risk-based margin treatment or 60-40 tax treatment). 
  
 (ii) In the event CME lists Competitive Contracts (vis-a-vis the E-mini
S&P 500 Contract) for trading, the ***** period prior to the Launch Date of such Contracts shall be deemed the “Reference Year.” ***** following such Launch Date, and each ***** on the Launch Anniversary Date it shall be determined
whether, during the preceding *****, there has been a ***** or greater Attributable Decrease (as defined herein) in both E-mini S&P 500 Contract volume and S&P Market Share (as defined herein) compared to levels during the Reference Year.

  

 Page 8 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 An Attributable Decrease in E-mini S&P 500 volume shall be measured by the lesser of:
(1) the difference between the annual trading volume in the E-mini S&P 500 Contract during the Reference Year and the trading volume in the E-mini S&P 500 Contract during the ***** prior to the relevant Launch Anniversary Date; and
(2) the Normalized Volume in the Competitive Contract during such ***** period. “S&P Market Share” shall be the percentage of Total Volume represented by E-mini S&P 500 trading volume. 
  
 In the event there has been a ***** or greater Attributable Decrease in both
E-mini S&P 500 trading volume and S&P Market Share, then ***** following the date such decreases are calculated, the Attributable Decrease in E-mini S&P 500 volume and S&P Market Share shall be calculated a second time for the *****
period immediately prior to the date of the second calculation. 
  
 In the event that after such second calculation, E-mini S&P 500 volume and S&P Market Share remain below ***** of their levels in the *****, the licenses granted hereunder for the S&P 500 Index and its associated Marks shall
immediately become non-exclusive and continue for the remainder of the term of this Agreement on a non-exclusive basis. 
  
 In the event the license for the S&P 500 Index becomes non-exclusive pursuant to this Subsection 3(b)(ii), there shall be no further adjustment to the
license fees paid to S&P by CME for Indexed Contracts that use the S&P 500 Index pursuant to Subsection 5(g), and such license fees shall be the Basic License Fee described in Section 5(a) and the fee specified in Section 5(c) with
respect to the E-mini S&P 500 Contract, adjusted, if applicable, pursuant to Section 5(b), for the remainder of the term of this Agreement. 
  
 (c) Non-S&P 500 Index. 
  
 (1) For any Sector-based Index or Emerging Index for which an Indexed Contract is listed after the Effective Date, CME’s exclusive
rights will automatically extend for ***** years from the listing of the first Indexed Contract on each such index CME’s exclusivity for each such index shall continue on ***** basis so long as the Indexed Contracts on each such index
collectively achieve an average daily volume (ADV) of *****. The ADV shall be measured over the ***** immediately preceding the anniversary of the listing of the first Indexed Contract on the relevant index. 
  
 (2) For any S&P Stock Index that is not a Sector-based
Index or Emerging Index for which an Indexed Contract is listed after the Effective Date, the exclusivity shall be for ***** years. CME shall maintain the exclusivity for each such S&P Stock Index that has Contracts that collectively achieve an
ADV of ***** by the ***** anniversary of trading. The ADV shall be measured over the ***** immediately preceding the ***** anniversary of the listing of the first such Indexed Contract. For all subsequent years, CME shall retain exclusivity if the
ADV threshold of ***** is met by the subsequent anniversary of the listing of the first such Indexed Contract, as measured over the preceding *****. 
  

 Page 9 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 For the purpose of subsections (b) and (c) above, the total volume of all
Indexed Contracts that use a single S&P Stock Index shall be cumulated to calculate the ADV. 
  
 (3) CME’s exclusive rights to the S&P Small Cap 600 index will automatically extend through January 1, 2008. For each *****
thereafter, CME shall maintain the exclusivity for the S&P Small Cap 600 index if the Indexed Contracts that use that index collectively achieve an ADV of ***** by January 1 of the relevant year. The ADV shall be measured over the *****
immediately preceding the relevant January 1. 
  
 (4) Indexed Contracts are most likely to succeed if both CME and S&P devote commercially reasonable efforts to promoting the underlying index and, as applicable, the related Contracts to the relevant target market. Consequently, if CME
fails to meet an ADV target specified in this Section 3, at CME’s request prior to any expiration of CME’s exclusive rights, S&P agrees to meet and discuss with CME in good faith whether the period of exclusivity should be
extended and promotional efforts enhanced before CME’s exclusive rights are terminated. However, if after good faith discussions S&P determines in its sole discretion that the product is more likely to succeed if it is not listed
exclusively at CME, S&P shall have the right to terminate CME’s exclusivity under the relevant license within three months after the discussions between CME and S&P have ended. It is recognized by the parties that S&P has no
obligation or current intention to market and promote Indexed Contracts. 
  

	4.	RIGHT OF FIRST REFUSAL ON NEW S&P STOCK INDICES. 

  
 During the term of this Agreement, CME shall have a right of first refusal on licenses to base Indexed Contracts on any stock indices not licensed
hereunder as of the Effective Date, and which are developed and compiled ***** during the term of this Agreement. CME shall not receive a new right of first refusal on any index that CME failed to accept the right of first refusal on between
September 24, 1997 and the Effective Date. Prior to offering any such license to any other party, S&P must first offer the license on an exclusive basis to CME. S&P must provide CME with reasonably sufficient information on which to
base its acceptance or rejection of S&P’s offer, including, without limitation, information and data (if available) indicating the amount of assets benchmarked to such index. CME shall have sixty (60) calendar days thereafter to accept
the offered license, in writing, on mutually agreeable terms, or to reject the offered license. However, if no agreement with respect to the offered license is reached between CME and S&P, S&P shall not grant such license to another party on
more favorable terms than were offered to CME. 
  
 CME agrees to
list Indexed Contracts on any such stock index that it accepts a license for within one year of such license becoming effective. This one year time limit shall be adjusted for any regulatory delays that are not primarily attributable to CME’s
inactions. The one year time limit shall apply on an index-by-index basis and S&P ETF Contracts will be treated separately from Futures Contacts based directly on an index. With respect to any 

  

 Page 10 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 
proposed S&P ETF Futures Contract, the one year period shall begin only once the following requirements are met: (1) the proposed S&P ETF
Futures Contract has met CME listing standards as set forth in Section 6 of the CME Rule Book, (2) trading in the underlying S&P Index ETF has achieved an average daily trading volume of at least ***** shares during the *****
immediately prior to the request and (3) CME has been trading a Futures Contract based directly on the S&P Stock Index underlying the S&P Index ETF for at least *****. 
  
 If CME does not launch an Indexed Contract on the relevant S&P Stock Index or S&P Index ETF within *****, S&P
shall have the right to terminate CME’s license for such S&P Stock Index, or to terminate CME’s exclusive rights with respect to such S&P Stock Index. S&P shall have sole discretion with regard to terminating CME’s rights
but must such termination must occur, if at all, within *****. 
  

	5.	LICENSE FEES. 

  
 (a) Basic License Fee. Subject to the terms and conditions of this Agreement, CME shall pay S&P $***** for each Contract traded with respect to
the current “big” S&P 500 Contract (i.e., for this purpose, the Contract that has been listed on CME since 1982, the current multiplier of which is $250 (the “Big Contract”) and $***** for each Contract traded with respect to
any other Indexed Contract, through and including the date on which this Agreement is terminated or expires pursuant to the terms hereof, except as otherwise specifically provided for in this Section 5. 
  
 (b) License Fees if Multiplier of Big Contract is Adjusted. If CME, in
its sole discretion, adjusts the multiplier of the Big Contract, the basic license fee described in Section 5(a) will be proportionately adjusted on a prospective basis as of the date of such change. CME shall provide S&P with at least
thirty (30) days advance written notice of such change, which notice shall specify the adjustment to S&P’s license fee. ***** thereafter, and for so long as CME trades Contracts that use the S&P 500 Index and that have a multiplier
of *****, and so long as the S&P 500 Index is licensed to CME on an exclusive basis, CME will compare the fees paid to S&P during the ***** period preceding ***** of the adjustment date, in regard to such Contracts, with the average annual
fee paid to S&P therefor during the ***** period prior to the first day that the adjusted Big Contract was listed for trading. If the total license fee paid to S&P for the S&P 500 Index in such ***** period is less than the average
annual license fee for the S&P 500 Index for such ***** period, CME shall pay S&P the difference within sixty (60) days of the relevant ***** of the adjustment date. Notwithstanding the foregoing, under no circumstances shall CME be
required to pay S&P more than $***** per Contract traded. An example of the above-described calculation is included in Appendix 5. 
  
 CME shall adjust the multiplier of any existing or future Indexed Contract only in the event that CME determines, in its sole discretion, that such an
adjustment will result in an increase in revenue to both CME and S&P. 
  

 Page 11 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 (c) S&P 500 E-mini-Contract. Subject to Section 5(g), for the E-mini S&P 500
Contract as currently structured (i.e., that has a contract multiplier of $50), CME shall pay S&P a per-Contract license fee equal to $*****. 
  
 (d) S&P ETF Contracts. CME shall pay S&P $***** for each S&P ETF Contract traded. Such license fees shall be paid in accordance with
Sections 5(e) and 5(f) of this Agreement. 
  
 (e) New Big-Sized
Contracts. Subject to Section 5(g), for each Indexed Contract (excluding S&P ETF Contracts) first listed after the Effective Date with an initial Notional Value greater than $100,000, CME shall pay S&P $***** per Contract traded.

  
 (f) Mini Contracts. For each Indexed Contract
(excluding S&P ETF Contracts), regardless of the date when it was first listed, and with an initial Notional Value of less than or equal to $100,000, CME shall pay S&P a per-Contract license fee equal to $*****. 
  
 (g) License Fee Adjustments if Contract that uses a Competitive Index is
Traded. If, after September 24, 1997 CME began trading Competitive Contracts, or if after the Effective Date CME begins trading Competitive Contracts, CME shall compensate S&P for any decrease in volume in the Indexed Contracts affected
by such Competitive Contracts (“S&P Affected Contracts”) that is not attributable to the normal decrease in trading volume for all Indexed Contracts. As compensation for any such decrease in volume, S&P shall, in respect of each
such S&P Affected Contract, be paid the lesser of the following: (1) the loss in volume (defined as the difference between the average annual volume for the ***** period preceding the Launch Date of Competitive Contracts and the volume in
each such S&P Affected Contract during the ***** period following such Launch Date) multiplied by the per-Contract license fee paid to S&P for the S&P Affected Contract during that ***** period; or (2) the Normalized Volume of the
Competitive Contract multiplied by the per-Contract license fee paid to S&P for the S&P Affected Contract during that period. The calculations described in this Section 5(g) shall be made, on each Launch Anniversary Date for the
Competitive Contracts, in ***** that Competitive Contracts are traded, with the ***** period in question recalculated on a rolling basis. Amounts payable to S&P hereunder shall be paid within sixty (60) days of the relevant Launch
Anniversary Date. An example of this calculation is included in Appendix 6. 
  
 In the event CME reduces the Notional Value of the S&P Affected Contract either prior or subsequent to its listing Competitive Contracts for trading, CME shall pay to S&P the lesser of the amounts calculated
pursuant to Section 5(b) or 5(g). 
  
 (h) Payment
Schedule. The license fees payable pursuant to this Section 5 shall be determined at the end of each month and shall be paid within fifteen (15) days after the end of each month. Each payment shall be accompanied by a full accounting
of the basis for the calculation of the fee. The amounts required to be paid pursuant to Sections 5(b) or (g) shall be payable in accordance with such sections and shall be accompanied by a full accounting of the basis for the calculation of
the payment. 
  

 Page 12 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 (i) Right to Audit. During the term of this Agreement and for a period of one (1) year
after its termination or expiration, S&P shall have the right, during normal business hours and upon reasonable notice to CME, to audit on a confidential basis the relevant books and records of CME to determine that the license fees, and other
amounts payable hereunder, have been accurately calculated. The costs of such audit shall be borne by S&P unless it determines that it has been underpaid by five percent (5%) or more; in such case, the costs of the audit shall be paid by
CME. 
  
 (j) Fee Reductions for Unlicensed Use by Competitive
Markets. 
  
 If a Competitive Market is engaged in unlicensed
trading of a product that is included in the scope of CME’s exclusive rights hereunder and (1) that unlicensed product is “related” to (as described below in this Section 5(j)) an Indexed Contract already trading on CME (a
“CME Affected Indexed Contract”) and (2) CME suffers a decline in its gross revenues from that CME Affected Indexed Contract, then the license fees payable by CME in the future with respect to the CME Affected Indexed Contract will be
reduced as follows: 
  
 If the decline in CME’s gross
revenues is at least *****, then, subject to the conditions below, CME will receive a reduction in the applicable fee equal to the percentage decline in CME’s gross revenues, plus *****, up to a maximum reduction of ***** lower than the fee
defined in Section 5(a) to (f). For example: 
  

	 	•	 	If CME experiences a ***** decline in gross revenues, there will be no reduction in the applicable fee 

  

	 	•	 	If CME experiences a ***** decline in gross revenues, the applicable fee will be reduced by ***** 

  

	 	•	 	If CME experiences a ***** or greater decline in gross revenues, the applicable fee will be reduced by ***** 

  
 The decline in CME gross revenues will be measured annually as follows:

  

	 	i.	The expected annual volume growth rate for the CME Affected Indexed Contract shall be estimated based upon the lowest of the following (including any negative growth rates): *****,
in each case for the period immediately prior to the initial launch of the unlicensed product.

  

	 	ii.	Project the expected CME ADV for the CME Affected Indexed Contract for the next ***** years by applying the expected annual volume growth rate determined in subsection i above to
the ADV of the CME Affected Indexed Contract for the ***** immediately prior to the initial launch of the related unlicensed product. 

  

	 	iii.	Determine the expected gross revenues for the CME Affected Indexed Contract the next ***** years by multiplying the expected annual volumes determined in subsection ii above by
CME’s average revenue rate per contract traded in the CME Affected Indexed Contract for the ***** period immediately prior to the initial launch of the unlicensed product. 

  

	 	iv.	Determine a revenue shortfall amount by subtracting the actual annual revenues from the expected annual revenues determined in subsection iii above. 

  

 Page 13 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

	 	v.	Determine the percentage of revenue decline, if any, by dividing the revenue shortfall amount into the expected annual revenue. 

  

	 	vi.	Calculate the appropriate adjustment to rates as set out above for each year, which CME may take as credit against payable fees in the following calendar year.

  

	 	vii.	Except as provided below, the rate reduction that applies for the ***** year shall continue for the duration of the term of this Agreement unless in the final ***** of the third
year CME achieves or exceeds the expected annual ADV for the ***** year. 

  
 However, CME will not be entitled to any adjustment in rates for a particular year if any of the following conditions apply: 
  

	 	1.	CME’s actual ADV in the CME Affected Indexed Contract for such year exceeds the expected CME ADV calculated in subsection ii above; or 

  

	 	2.	the Notional Value traded in the unlicensed product is less than ***** of the Notional Value expected to be traded in the CME Affected Indexed Contract; or 

 

	 	3.	the decline in CME’s actual ADV in the CME Affected Indexed Contract versus the expected CME ADV can be substantially attributed to a change in the regulatory treatment or tax
treatment that applies to the CME Affected Indexed Contract or a material business failure on CME’s part that has substantially impacted trading volumes in CME products generally (for example, without limitation, a major scandal in CME’s
markets that damages CME’s reputation and negatively impacts trading). 

  
 If, after there has been one or more adjustments to the rates for a CME Affected Indexed Contract pursuant to the foregoing and the competitive unlicensed product that precipitated such adjustment in rates stops
trading on a Competitive Market then, effective on the first day of the next calendar month, the rates payable by CME for the CME Affected Indexed Contract shall revert to the rates that applied prior to the time of the first adjustment. CME would
remain eligible in such event for reduced fees under this Section 5(j) if in the future another such competitive unlicensed product is listed on a Competitive Market. 
  
 If there are multiple competitive unlicensed products being listed, the following will apply: 
  

	 	(i)	During any ***** period that is triggered by the listing of a competitive unlicensed product, the trading volume of all competitive unlicensed products that are listed during such
period will be aggregated for purposes of determining whether the Notional Value requirement in subsection ii above is satisfied for any *****. 

  

	 	(ii)	 If a permanent fee reduction under Section 5(j)vii applies, and a new competitive unlicensed product is listed or the same competitive unlicensed product is
listed on a new Competitive Market (in either case impacting the CME Affected Indexed Contract as to which the permanent reduction applies), then a new ***** period will begin, based upon newly-calculated volume and revenue estimates, and CME will
be eligible for further reductions based upon the formula above if CME again experiences a qualifying decline in gross 

  

 Page 14 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

	 	 
revenues. Any such reduction would be applied only as an increase to the existing percentage reduction applied against the original applicable fee specified
in Section 5(c) and would not be a compounding of reductions. For example, if a ***** fee reduction has become permanent with respect to a particular CME Affected Indexed Contract and a new ***** period is begun on the basis of a new
competitive unlicensed product: 

  

	 	•	 	If CME experiences a ***** decline in gross revenues, there will continue to be a ***** fee reduction 

  

	 	•	 	If CME experiences a ***** decline in gross revenues, the fee reduction would be increased to ***** 

  

	 	•	 	If CME experiences a ***** or greater decline in gross revenues, the fee reduction would be increased to ***** 

  
 S&P will have the right to conduct a reasonable audit on a confidential
basis of CME’s books and records related to trading volumes and gross revenues in the CME Affected Indexed Contract if CME asserts that it is entitled to a reduction in rates pursuant to the foregoing. 
  
 For purposes of this Section 5(j), an unlicensed product will be deemed
to be “related” to an Indexed Contract even if it is not equal to an Indexed Contract (such that CME did not have the right to eliminate license fees or terminate this Agreement) but is designed to substantially replicate the economic
performance of an Indexed Contract such that the use of the unlicensed product may effectively be substituted for the use of the Indexed Contract with little or no difference in market risk. For example, an unlicensed S&P ETF Contract offered by
a Competitive Market would be related to a broad-based Indexed Contract that is settled to the same S&P Stock Index as underlies the S&P Index ETF. 
  

	6.	TERM. 

  
 The term of this Agreement shall commence as of the Effective Date and shall continue in full force and effect until December 31, 2017, unless and
until terminated earlier in accordance with Section 7 hereof. 
  

	7.	TERMINATION. 

  
 (a) Material Breach. In the case of a breach of any of the material terms or conditions of this Agreement by either party, the other party may
terminate this Agreement by giving thirty (30) days prior written notice to the non-breaching party of its intent to terminate, which notice shall specify the nature of the alleged breach, and such notice shall be effective on the date
specified therein for such termination unless the breaching party shall correct such breach within the notice period. In addition, at any time during the term of this Agreement, either party may give the other party ninety (90) days prior
written notice of termination if the terminating party believes in good faith that material damage or harm is occurring to the reputation or goodwill of the terminating party by reason of its continued performance hereunder, and such notice shall be
effective on the date specified therein of such termination, unless the other party shall correct the condition causing such damage or harm within the notice period. 
  

 Page 15 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 (b) Discontinuation of an S&P Stock Index. S&P shall have the right in its sole
discretion to cease compilation and publication of any of the S&P Stock Indices without liability hereunder and, upon prompt written notice to CME of such discontinuance and subject to Section 8 hereof, to terminate the license granted
hereunder as to such discontinued S&P Stock Index and the associated S&P Marks; provided, however, that S&P shall use its best efforts to give CME at least one (1) year prior written notice of such discontinuation and further
provided, however, that all Indexed Contracts that use the discontinued S&P Stock Index which are open and listed for trading on the date of such notice of termination was provided to CME, may nevertheless continue to be traded until such
Indexed Contracts either expire and are no longer listed for trading or until thirty-six (36) months following the date of such notice of termination, whichever occurs first. CME’s obligations to make payment to S&P with respect to any
Indexed Contract licensed pursuant to this Agreement and that use the discontinued Index shall terminate effective on the date on which the license for the discontinued Index is effectively terminated by S&P. 
  
 (c) Cessation of Trading in or De-Listing of an S&P ETF. S&P
shall inform CME in writing if S&P becomes aware of any pending cessation of trading in, or de-listing of, an S&P ETF. S&P shall have no other obligations to CME under this Agreement in connection with the cessation of trading in, or
de-listing of, an S&P ETF. CME understands that during the term of this Agreement, one or more of the S&P Index ETFs may be de-listed or otherwise cease trading and in such event, S&P shall have no liability to CME arising out of such
de-listing or cessation. CME acknowledges that the de-listing of, or cessation in trading in, an S&P Index ETF can and will affect CME’s ability to continue to create, issue, list, trade, clear, market, and promote the associated S&P
ETF Contracts. 
  

	8.	CME SUBSTITUTE INDEX AND CONTRACTS. 

  
 (a) CME’s Rights Upon Discontinuation of an S&P Stock Index. Excluding with respect to S&P ETF Contracts, if S&P discontinues
compilation and publication of any S&P Stock Index licensed to CME under this Agreement, CME shall have the following rights: 
  
 (1) S&P shall, for the purpose of enabling CME, if CME chooses, to compile and make use of its own substitute index (“CME
Substitute Index”) with respect to any discontinued S&P Stock Index, provide CME with a continuing non-exclusive and royalty-free worldwide license to use the list of companies, shares outstanding and divisors for such discontinued S&P
Stock Index as of the Index Discontinuation Date. S&P shall have no further obligations to CME with respect to such discontinued S&P Stock Index or any Indexed Contract based upon such Index after furnishing CME with the aforesaid
information. 
  
 (2) As of the Index
Discontinuation Date, CME shall not trade any Indexed Contracts based upon the discontinued S&P Stock Index except as provided in Section 7(b) of this Agreement and as follows: Upon receipt of any notice of index discontinuation by S&P
hereunder as provided in Section 7(b), CME may elect, by written notice to S&P, to redesignate the discontinued S&P Stock Index as a CME Substitute Index and continue to trade Indexed 

  

 Page 16 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 
Contracts (“CME Substitute Contracts”) based upon such CME Substitute Index, except that, from the date of such notice of election until the Index
Discontinuation Date of such S&P Stock Index, such CME Substitute Index shall be described in a manner to clearly differentiate it from the discontinued S&P Stock Index. CME shall have no obligation to make any payment of fees to S&P
with respect to the trading of CME Substitute Contracts that occurs after the Index Discontinuation Date. After such election, CME may promote CME Substitute Contracts based upon the CME Substitute Index provided that the S&P Marks are not
utilized by CME in connection therewith and CME prominently disclaims any relationship with S&P with respect to the CME Substitute Contracts. 
  
 (b) Discontinuation of Trademark Licenses. If CME’s license to use any S&P Stock Index terminates because of the termination or expiration
of this Agreement, or for any reason other than S&P’s discontinuation of its compilation and publication, then CME shall not use the name “Standard & Poor’s” or “S&P” or “CITIGROUP” in
connection with the promotion or trading of any additional Indexed Contracts that use such S&P Stock Index; provided, however, that Indexed Contracts that use such S&P Stock Index, which are listed for trading on the date of termination, may
be traded using the relevant S&P Marks until expiration or for 36 months, whichever occurs first. Following such termination, if CME elects to trade CME Substitute Contracts on a CME Substitute Index, it may make information references only to
such S&P Stock Index, provided that CME disclaims any relationship with S&P in connection therewith. The foregoing shall nevertheless depend on the fact that S&P shall continue to compile and publish such S&P Stock Index in which
event S&P shall disseminate such Index to CME in the same fashion as is currently being done, except that CME shall bear any incremental costs incurred by S&P at any time in providing such service. 
  
 (c) S&P/CITIGROUP Indices. If at any time during the term of this
Agreement, CITIGROUP for any reason ceases participating in the compilation and publication of the S&P/CITIGROUP Indices thereby preventing S&P from continuing to license them to CME hereunder, S&P covenants and agrees that it shall,
without interruption, itself compile and publish substantially similar substitute indices for CME’s use under the terms of this Agreement, and S&P shall have no other obligations, and no liability, to CME hereunder arising out of CITIGROUP
ceasing to participate in the compilation and publication of the S&P/CITIGROUP Indices. In such event, the parties agree that such substitute indices shall replace the S&P/CITIGROUP Indices under this Agreement and that new trademarks will
be designated to replace the S&P/CITIGROUP Marks, and that CME’s use of the S&P/CITIGROUP Indices and S&P/CITIGROUP Marks shall cease. It is understood that the licensing of any such substitute indices shall be evidenced by a
written amendment to this Agreement, executed by S&P and CME. 
  

	9.	S&P OBLIGATIONS. 

  
 (a) Regulatory Approvals or Investigations. S&P shall reasonably assist CME in connection with the preparation of factual materials for
presentation to the CFTC, or any other governmental entity, in connection with any application by CME for approval to trade any of the Indexed Contracts licensed hereunder, or any investigations or hearings regarding any such Indexed Contracts.

  

 Page 17 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 (b) Calculation and Dissemination of Index Values. S&P or its agent shall compute and, in
a manner reasonably satisfactory to CME, disseminate to CME, the value of each of the S&P Stock Indices at least once every fifteen seconds during normal trading hours. The foregoing shall be at S&P’s expense, except that S&P shall
not be obligated to pay for any hardware, software, communications or similar expenses associated with the receipt by CME of S&P Stock Index values. S&P, or its agent, shall provide CME each trading day with respect to each S&P Stock
Index licensed to CME hereunder a special opening quotation for use in settling Indexed Contracts that use such S&P Stock Index as well as the percentage of underlying stocks that have opened trading that day in the primary market or that have
resumed trading after a trading halt in the primary market. *****. Subject to Section 13 hereof, S&P shall use commercially reasonable efforts to provide correct and timely calculation and dissemination of the S&P Stock Indices and use
its best efforts to (1) maintain a backup to verify the calculation of the S&P Stock Indices on a continuing basis; (2) take extra precautions to verify the accuracy of the daily closing index values; and (3) inform CME each day
of the closing numbers for each of the S&P Stock Indices as soon as practicable after the close of trading of the underlying stocks. 
  
 (c) Third Party Trademarks and Intellectual Property. CME acknowledges that certain designations used in the names of the S&P ETFs (e.g.,
“iShares”) and other intellectual property rights embodied therein belong to third parties. No rights to use trademarks or other intellectual property belonging to third parties, with the exception of the S&P/Citigroup Indices and the
S&P/Citigroup Marks, are conveyed by this Agreement. S&P shall reasonably cooperate with CME in acquiring such rights to the extent such rights are necessary for CME to create, market, trade, clear or promote S&P ETF Contracts, however,
CME is solely responsible for securing all necessary licenses to use third- party trademarks and intellectual property. 
  

	10.	CME’s OBLIGATIONS. 

  
 (a) General. CME shall use its best efforts to protect the goodwill and reputation of S&P and of the S&P Marks in connection with their use
under this Agreement. CME shall maintain high standards of fairness and truthfulness in, and shall allow S&P, upon its request, to review and approve in advance, all CME advertisements, brochures, promotional and informational materials relating
to or referring to the S&P Stock Indices or the Indexed Contracts. S&P shall safeguard the confidentiality of any promotional or informational materials furnished by CME for S&P’s review, as provided for in Section 12(b)
hereof. 
  
 (b) Compliance with Applicable Laws. CME shall
use its best efforts to comply with the federal commodities laws and the rules there under insofar as those laws and rules relate to the Indexed Contracts licensed hereunder. CME shall take all necessary steps to ensure that the trading of the
Indexed Contracts is carried out in accordance with high ethical and legal standards. S&P shall have no obligation or liability in connection therewith. This provision is intended solely for the benefit of the parties hereto and not for the
benefit of third parties. 
  

 Page 18 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 (c) CME Rulebook Disclaimers. CME shall use and disseminate the S&P Stock Indices and the
S&P Marks only in compliance with the terms and conditions of this Agreement to ensure that S&P’s rights in the S&P Stock Indices and the S&P Marks are in no way diminished or jeopardized and CME shall use its best efforts to
ensure that the public is in no way confused or misled as to such rights. CME shall include the limitation on liability and disclaimers set forth in Appendix 4 to this Agreement in its rules, and take any other action necessary to ensure that its
members trading in Indexed Contracts are aware of the disclaimers and aware of, and subject to, the limitation on liability set forth in Appendix 4. 
  
 (d) Cross-Margining Program. CME will use its best efforts to include the Indexed Contracts in CME’s existing cross-margining program with the
Options Clearing Corporation unless CME reasonably determines in any case that such cross-margining program is not appropriate. 
  
 (e) Regulatory Approvals. CME shall promptly file for and use its best efforts to obtain and maintain any regulatory approval for the trading of
Indexed Contracts that is required during the term of this Agreement. 
  
 (f) CME Warranties. The CME represents and warrants to S&P that (1) the execution and performance of this Agreement by the CME will not conflict with, or result in a breach or violation of, any other agreement (written or
oral) or instrument to which CME is party or by which it is bound, and (2) this Agreement has been duly authorized, executed and delivered by CME and constitutes a valid and legally binding obligation of CME, enforceable in accordance with its
terms. 
  
 (g) Listing of New Indexed Contracts. In
addition to its obligations under Section 2(f), CME shall promptly inform S&P in advance of each proposed listing by CME of any Indexed Contract that is not listed on CME as of the Effective Date. This obligation does not apply to the
listing of new contract months (expirations). 
  

	11.	PROTECTION OF VALUE OF LICENSE. 

  
 (a) Trademark Registrations. During the term of this Agreement, S&P shall use its best efforts to maintain in full force and effect U.S.
federal registrations of “Standard & Poor’s®,” “S&P®” and “S&P 500®.” CME shall reasonably cooperate with S&P, at S&P’s expense, in the maintenance of such rights and registrations and shall do such acts and execute such instruments as are reasonably necessary and
appropriate for such purposes. 
  
 (b) Unlicensed Use of
S&P Stock Indices or S&P Marks. In the event S&P is notified by CME or otherwise becomes aware that any of the S&P Stock Indices that have been licensed exclusively to CME hereunder, or associated S&P Marks, are to be or have
been used by a Competitive Market without the prior written consent of S&P, in connection with the trading by such Competitive Market of Indexed Contracts that are traded by CME hereunder (“Unlicensed User”), and that such use has or
may reasonably be expected to have a material adverse impact upon the benefits derived by CME from the licenses hereunder with respect to the 

  

 Page 19 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 
Indexed Contracts that are made available for trading by the Unlicensed User (“Impacted Indexed Contracts”), S&P shall have the option to
either (i) use its best efforts to terminate such use, including, without limitation, by initiating litigation against any such Unlicensed User; or (ii) permit such Unlicensed User to continue such use, in which case CME shall have the
rights provided below. S&P shall have thirty (30) days after being notified in writing by CME of such unlicensed use in which to notify CME of S&P’s decision whether to seek to terminate such use or permit it. 
  
 If S&P chooses to take action to terminate such unlicensed use, CME shall
continue to pay the license fees required hereunder to S&P during any litigation relating to such unlicensed use, whether index-based or ETF-based, that is in violation of CME’s exclusive rights granted in this Agreement. Such payments will
continue unless and until a court of competent jurisdiction (including but not limited to a court of first instance) issues a final ruling adverse to S&P. If the ruling allows the unlicensed use to continue, S&P shall reimburse CME for all
license fees paid by CME for the Impacted Indexed Contracts subsequent to S&P’s receipt of notice from CME of the unlicensed use, and CME’s obligation to pay license fees shall, except as provided below, cease going forward. For the
avoidance of doubt, CME’s reimbursement right applies only to the Impacted Indexed Contract listed by CME and not fees paid for any other Indexed Contract. If an adverse ruling is later reversed on appeal, CME shall pay to S&P a sum equal
to (a) all license fees that S&P previously reimbursed to CME, plus (b) any license fees that CME would have paid to S&P under the terms of the license during the pendency of the appeal, less (c) any damages that S&P is
able to collect relating to loss of license fees on subsequent review by the trial court (excluding any recovery of S&P’s outside counsel costs and expenses associated with the litigation). 
  
 With respect to S&P ETF Contracts, it is understood that if the current
litigation between S&P and International Securities Exchange, Inc. (“ISE”) is finally adjudicated, including through all avenues of appeal, and it is determined that ISE is not required to obtain a license from S&P in order to list
and trade SPDR options, then S&P will have sixty (60) days to notify CME whether it intends in the future to challenge the unlicensed trading of S&P ETF Contracts. If S&P determines that it will not challenge any such unlicensed
use, then upon notice to CME, S&P will no longer be required to protect the value of CME’s exclusive license with respect to S&P ETF Contracts and CME will not be required to remit license fees to S&P as a result of the trading of
S&P ETF Contracts by CME. If S&P informs CME within such sixty (60) day period that it will challenge any such unlicensed use, then CME will continue to pay license fees to S&P for S&P ETF Contracts and the two preceding
paragraphs with respect to unlicensed use will apply. 
  
 The
right to receive the reimbursement described above and the elimination of future license fee obligations (if S&P declines to appeal an adverse ruling or is unsuccessful in doing so) will represent CME’s sole and exclusive remedy against
S&P in the event of such a ruling in S&P’s litigation with ISE (i.e., CME shall have no cause of action against S&P, including without limitation for loss of future business profits, due to such a ruling or a decision by S&P not
to contest the trading by a Competitive Market of S&P ETF Contracts following a ruling as described above in connection with such litigation). CME’s reimbursement right will continue to 

  

 Page 20 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 
apply only with respect to payments made by CME that relate to the S&P ETF Contracts and not to other Indexed Contracts. 
  
 With respect to any effort by S&P short of litigation to terminate a
third party’s unlicensed use of the exclusively licensed S&P Stock Indices and associated S&P Marks as contemplated under this Subsection 11(b), S&P shall, within ten (10) days, give written notice to CME of any decision to
cease such effort to terminate such unlicensed use and of any adverse final decision in a litigation regarding same, by any court or other governmental body as to which there is no further appeal. 
  
 The costs of any litigation brought under this Subsection 11(b) shall be
borne entirely by S&P. CME may, in its sole discretion, join any such litigation in order to protect its rights including seeking monetary damages. S&P will continue to have sole control over such litigation at its option where CME
voluntarily joins a lawsuit initiated by S&P. However, CME shall have sole control over its own decisions as a party to any causes of action separately initiated by CME, even if subsequently joined with a lawsuit initiated by S&P; provided,
however, that in no event will CME be permitted to initiate a separate litigation challenging the unlicensed use of the S&P Stock Indices and/or S&P Marks unless S&P has first elected not to initiate litigation in response to such
unlicensed use as contemplated under this Section 11(b). 
  
 In the event litigation initiated pursuant to this Section 11(b) is decided adversely to S&P through all avenues of appeal, or if S&P is otherwise unsuccessful in terminating such party’s use of the Impacted Indexed
Contract, or if S&P notifies CME that it will not challenge such unlicensed use, then: 
  
 (1) S&P shall have no further liability to CME hereunder on account of such use and shall not be deemed to have breached any of its
representations, warranties or agreements hereunder. Notwithstanding the foregoing, while this Agreement remains in effect, S&P shall not enter into any agreement, written or oral, with any third party, pursuant to which S&P will receive
revenue, derived from the trading of the Impacted Indexed Contracts; 
  
 (2) CME shall have the right to terminate this Agreement relating to the *****, along with all rights and obligations of the parties thereto, except for *****, provided that CME gives written notice of such
termination to S&P within thirty (30) days of receiving written notice from S&P that it will not seek to terminate such unlicensed use or that its efforts to terminate such unlicensed use have been unsuccessful; and 
  
 (3) if CME does ***** hereby to the *****, the total license
fees payable by CME under this Agreement in connection with all the ***** shall, for the duration of the term of this Agreement, immediately be reduced to $*****. 
  
 It is understood that the rights and obligations under this Subsection 11(b) are exclusively in relation to the *****
arising from any unlicensed use of the S&P Stock Indices or S&P Marks. To remove any doubt, if an Unlicensed User trades an Indexed Contract without a license and S&P, as contemplated in the first paragraph of this Subsection 11(b),
elects not to seek to terminate such use, CME may choose to continue the license and pay the $***** fee for its continued trading of the *****. In such a case, CME would still be obligated to pay the license fees for trading other Indexed Contracts.

  

 Page 21 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 (c) Unlicensed Use by Entities Other Than a Competitive Market. If an entity that is not a
Competitive Market lists for trading an unlicensed product in violation of CME’s exclusive rights, S&P shall use commercially reasonable efforts to prevent such unlicensed use. However, if S&P determines in its discretion that its
interests in preserving its intellectual property are best served by not challenging such use, or by granting a license to the unlicensed user, S&P may do so. If S&P grants such a license, CME will be entitled to receive ***** of the license
fees paid to S&P under the license. Unlicensed or licensed use (as provided above) by an entity that is not a Competitive Market will not be deemed a breach of S&P’s obligations under this Agreement. For the avoidance of doubt, the
parties agree that “contracts for differences” that utilize the S&P 500 Index and as of the Effective Date are being offered for trading via the Internet outside of the U.S., fall into this category, and CME’s rights to protection
against such trading will be limited to the right to receive its share of license fees if S&P decides to license such use. 
  

	12.	PROPRIETARY RIGHTS. 

  
 (a) Security Measures. CME acknowledges that the S&P Stock Indices, including the S&P/CITIGROUP Indices, are valuable assets of, and are
selected, coordinated, arranged and prepared solely by S&P, and S&P and CITIGROUP, respectively, through the application of methods and standards of judgment used and developed through the expenditure of considerable work, time and money.
CME agrees that it will take such security measures as are reasonably necessary in order to prevent any unauthorized use of the information provided to it concerning the selection, coordination, arrangement and preparation of the S&P Stock
Indices, including the S&P/CITIGROUP Indices. 
  
 (b)
Obligations of Confidentiality. Each party shall treat as confidential, and shall not disclose or transmit to any third party: (1) any documentation or other materials that are marked as “Confidential and Proprietary” by the
providing party; or (2) the terms of this Agreement (“Confidential Information”). Confidential Information as described in clause (1) of the preceding sentence shall not include: (A) any information that is available to the
public or to the receiving party hereunder from sources other than the providing party (provided that such source is not subject to a confidentiality agreement with regard to such information); or (B) any information that is independently
developed by the receiving party without use of or reference to information from the providing party. Notwithstanding the foregoing, either party may reveal Confidential Information to any regulatory agency or court of competent jurisdiction if such
information to be disclosed is: (i) approved for disclosure in writing by the providing party; or (ii) required by law, regulatory agency or court order to be disclosed by the receiving party, provided, however, that if permitted by law,
prior written notice of such required disclosure shall be given to the providing party and further provided, however, that the receiving party shall cooperate with the providing party to limit the extent of such disclosure. 
  

 Page 22 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

	13.	REPRESENTATIONS, WARRANTIES, DISCLAIMERS. 

  
 (a) Rights to Grant Licenses. S&P represents and warrants that S&P is the owner of, or has the right to license CME to use, the S&P
Stock Indices and S&P Marks, as provided herein. S&P hereby represents and warrants to CME that CITIGROUP has consented to S&P’s entry into this Agreement with CME. 
  
 (b) Responsibilities for Errors and Omissions. S&P shall promptly correct, or instruct its agent to correct, any
errors made in S&P’s computations of the S&P Stock Indices that are brought to S&P’s attention by CME; provided, however, that nothing in this Section 13 shall give CME the right to exercise any judgment or require any
changes with respect to S&P’s method of composing, calculating or determining the S&P Stock Indices; and, further provided, however, that nothing in this Section 13(b) shall be deemed to modify the other provisions of this
Section 13. 
  
 (c) Limitation of Liability. S&P
shall obtain information for inclusion in or for use in the calculation of the S&P Stock Indices from sources that S&P considers reliable, but S&P accepts no responsibility for, and shall have no liability for, any errors, omissions or
interruptions therein. S&P does not guarantee the accuracy and/or the completeness of the S&P Stock Indices or any data included therein in connection with the trading of the Indexed Contracts, or any other use. S&P makes no warranty,
express or implied, as to results to be obtained by any person or any entity from the use of the S&P Stock Indices or any data included therein. S&P makes no express or implied warranties and expressly disclaims all warranties of
merchantability or fitness for a particular purpose or use with respect to the S&P Stock Indices or any data included therein. 
  
 (d) No Special Damages. Neither party shall have any liability for lost profits or indirect, punitive, special, or consequential damages (including
lost profits) arising out of this Agreement, even if notified of the possibility of such damages. 
  
 (e) Limitation on Damages. Without diminishing the disclaimers and limitations set forth in this Section 13, in no event shall the cumulative
liability of S&P to CME exceed the license fees actually paid to S&P hereunder over the one-year period preceding the date on which S&P is found liable to CME. The parties agree that this limitation on liability is reasonable under the
circumstances. 
  
 (f) Disclaimers, Limitations and
Indemnification. CME agrees that the disclaimers and limitations on liability that are set forth in Sections 13(b), (c), (d) and (e) of this Agreement and S&P’s rights of indemnification under Section 14 of this
Agreement, as modified hereby, shall apply to S&P ETF Contracts with equal effect as applied to Indexed Contracts, generally, under this Agreement. S&P represents and warrants that S&P has the right to license CME to use the S&P
Stock Indices and S&P Marks, as provided in the Agreement. 
  

 Page 23 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

	14.	INDEMNIFICATION. 

  
 (a) CME’s Indemnification of S&P. Except as provided in Subsection (b) below, CME shall indemnify and hold harmless S&P, its
affiliates and their officers, directors, employees and agents against any and all judgments, damages, costs or losses of any kind (including reasonable attorneys’ and experts’ fees) as a result of any claim, action, or proceeding that
arises out of or relates to: (1) this Agreement (other than a breach by S&P of its representations, warranties and agreements hereunder); or (2) the Indexed Contracts; provided, however, that S&P notifies CME promptly of any such
claim, action or proceeding. CME shall periodically reimburse S&P for its expenses incurred under this Section 14. S&P shall have the right, at its own expense, to participate in the defense of any claim, action or proceeding against
which it is indemnified hereunder; provided, however, it shall have no right to control the defense, consent or judgment, or agree to settle any such claim, action or proceeding without the written consent of CME without waiving the indemnity
hereunder. CME, in the defense of any such claim action or proceeding, except with the written consent of S&P, shall not agree to entry of any judgment or enter into any settlement which either does not include, as an unconditional term, the
grant by the claimant to S&P of a release of all liabilities in respect of such claims or which otherwise adversely affects the rights of S&P. 
  
 (b) Exclusion from CME’s Indemnification Obligation. CME’s indemnification obligations under Subsection (a) above shall not apply
to: (1) the willful or intentional misconduct of any of S&P’s officers, directors, employees, or agents; (2) ***** in the S&P Stock Indices or any data included therein originated by S&P; or (3) any breach by S&P
of its representations, warranties, or agreements made in this Agreement. 
  
 (c) No Third Party Beneficiaries. These indemnification provisions are solely for the benefit of CME and S&P and are not intended to, and do not create, any rights or causes of actions on behalf of any
third party. 
  

	15.	FORCE MAJEURE. 

  
 Neither S&P nor CME shall bear responsibility or liability for any losses arising out of any delay in or interruptions of their respective performance
of their obligations under this Agreement due to any act of God, act of governmental authority or act of public enemy or due to war, the outbreak or escalation of hostilities, riot, fire, flood, civil commotion, insurrection, labor difficulty
(including, without limitation, any strike, or other work stoppage or slow down), severe or adverse weather conditions, power failure, communications line failure, or other similar cause beyond the reasonable control of the party so affected.

  

	16.	INJUNCTIVE RELIEF. 

  
 In the event of a material breach by one party of provisions of this Agreement relating to the Confidential Information of the other party, the parties
acknowledge and agree that damages would be an inadequate remedy and that the non-breaching party shall be entitled to preliminary and permanent injunctive relief to preserve such confidentiality or limit improper disclosure of 

  

 Page 24 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 
such Confidential Information, but nothing herein shall preclude the non-breaching party from pursuing any other action or remedy for any breach or
threatened breach of this Agreement. In the event of a material breach by CME of provisions of this Agreement relating to dissemination of the S&P Stock Indices or the unauthorized use of the S&P Stock Indices or S&P Marks, CME
acknowledges and agrees that damages would be an inadequate remedy to S&P and that S&P shall be entitled to preliminary and permanent injunctive relief to enforce the provisions hereof, but nothing herein shall preclude S&P from pursuing
any other action or remedy for any breach or threatened breach of this Agreement. All remedies hereunder shall be cumulative. 
  

	17.	GENERAL PROVISIONS. 

  
 (a) Assignment and Delegation. This Agreement is solely and exclusively between the parties hereto and shall not be assigned or transferred, nor
shall any duty hereunder be delegated, by either party, without the prior written consent of the other party, and any attempt to so assign or transfer this Agreement or delegate any duty hereunder without such written consent shall be null and void.
This Agreement shall be valid and binding on the parties hereto and their successors and permitted assigns. 
  
 (b) Entire Agreement. This Agreement constitutes the entire agreement of the parties hereto with respect to its subject matter. This Agreement
supersedes the 1997 Agreement and all other previous agreements between the parties, if any, with respect to the subject matter of this Agreement, including without limitation those agreements listed in Appendix 3. There are no oral or written
collateral representations, agreements, or understandings except as provided herein. 
  
 (c) Non-Waiver and Amendments. No waiver, modification, or amendment of any of the terms and conditions hereof shall be valid or binding, unless such waiver, modification, or amendment is in writing and signed
by a duly authorized officer of each of the parties hereto. 
  
 (d) Effect of Breach. No breach, default or threatened breach or default of this Agreement by S&P shall relieve CME of its obligations under this Agreement with respect to the protection of the property or proprietary nature of
any property which is the subject matter of this Agreement. 
  
 (e) Notices. All notices and other communications under this Agreement shall be: (1) in writing; (2) delivered by hand, by registered or certified mail, return receipt requested, or by facsimile transmission to the address
or facsimile number set forth below or such address or facsimile number as either party shall specify by a written notice to the other; and (3) deemed given upon receipt. 
  

 Page 25 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 Notice to S&P: 
 Standard & Poor’s 
 55 Water
Street 
 New York, New York 10041 

			
	 Attention:
	  	Ms. Kathleen A. Corbet
President
	 Facsimile No:
	  	(212) 438-5723

  
 With a copy
to: 
 The McGraw-Hill Companies 
 1221 Avenue of the Americas 
 New York, NY 10020 

			
	 Attention:
	  	General Counsel
	 Facsimile No:
	  	(212) 512-4827

  
 Notice to
CME: 
 Chicago Mercantile Exchange 
 20 South Wacker Drive 
 Chicago, IL 60606 

			
	 Attention:
	  	Craig S. Donohue, CEO
	 Facsimile No:
	  	(312) 930-3207

  
 With a copy
to: 
 Chicago Mercantile Exchange 
 20 South Wacker Drive 
 Chicago, Illinois 60606 

			
	 Attention:
	  	General Counsel
	 Facsimile No:
	  	(312) 930-3323

  
 (f) Governing
Law. This Agreement shall be interpreted, construed and enforced in accordance with the laws of the State of New York. 
  
 (g) Choice of Jurisdiction. Each party agrees that in connection with any legal action or proceeding arising with respect to this Agreement, such
action or proceeding shall be brought only in the United States District Court for the Southern District of New York or in the Supreme Court of the State of New York in and for the First Judicial Department, and each party agrees to submit to the
jurisdiction of those courts and venue in those courts and to waive any claim that either court is an inconvenient forum. 
  
 (h) Survival. Section 12, Section 13 and Section 14 shall survive the expiration or termination of this Agreement. 
  

 Page 26 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the date first
set forth above. 
  

									
	STANDARD & POOR’S	 	 	 	CHICAGO MERCANTILE EXCHANGE INC.
					
	 BY
	 	/s/    KATHLEEN CORBET        	 	 	 	 BY
	 	/s/    CRAIG S. DONOHUE        
	 Name:
	 	Kathleen Corbet	 	 	 	 Name:
	 	Craig S. Donohue
	 Title:
	 	President	 	 	 	 Title:
	 	Chief Executive Officer
			
	 Date: October 31, 2005
	 	 	 	 Date: October 31, 2005

  

 Page 27 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 APPENDIX 1 
  
 The S&P Stock Indices collectively covered by and referred to in this Agreement are the following: 
  

	1.	S&P 500 Stock Price Index 

  

	2.	S&P 100 Stock Price Index 

  

	3.	S&P MidCap 400 Index 

  

	4.	S&P SmallCap 600 Index 

  

	5.	S&P 500/CITIGROUP Growth Index 

  

	6.	S&P 500/CITIGROUP Value Index 

  

	7.	S&P Energy Stock Price Index 

  

	8.	S&P Financial Stock Price Index 

  

	9.	S&P High Technology Stock Price Index 

  

	10.	S&P Public Utility Stock Price Index 

  

	11.	S&P Consumer Staple Stock Price Index 

  

	12.	S&P Transportation Stock Price Index 

  

	13.	S&P Euro Index 

  

	14.	S&P Euro Plus Index 

  

	15.	S&P Euro 350 Index 

  

	16.	S&P / TOPIX 150 Index 

  

	17.	S&P 500 GICS Sector Indices 

  

	18.	S&P Asia 50 

  
 Solely for the purposes of CME’s index value dissemination as provided in Appendix 7, CME shall have dissemination rights with respect to the following indices: 
  

	 	1.	S&P Euro 350 Finance Index 

  

 Page 28 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

	 	2.	S&P Euro 350 Information Index 

  

	 	3.	S&P Euro 350 Telecom Index 

  

	 	4.	***** 

  

	 	5.	S&P Global 1200 

  

	 	6.	***** 

  

	 	7.	***** 

  

	 	8.	***** 

  

	 	9.	***** 

  

	 	10.	***** 

  

 Page 29 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 APPENDIX 2 
  
 The S&P Marks collectively covered by and referred to in this Agreement are the following: 
  

	1.	S&P 

  

	2.	Standard & Poor’s 

  

	3.	Standard & Poor’s 500 

  

	4.	500 

  

	5.	S&P 100 

  

	6.	Standard & Poor’s 100 

  

	7.	S&P MidCap 400 Index 

  

	8.	Standard & Poor’s 100 

  

	9.	S&P SmallCap 600 Index 

  

	10.	Standard & Poor’s 

  

	11.	S&P 500/CITIGROUP Growth Index 

  

	12.	Standard & Poor’s 500/CITIGROUP Growth Index 

  

	13.	S&P 500/CITIGROUP Value Index 

  

	14.	Standard & Poor’s 500/CITIGROUP Value Index 

  

	15.	S&P Energy Stock Price Index 

  

	16.	Standard & Poor’s Energy Stock Price Index 

  

	17.	Standard & Poor’s Financial Stock Price Index 

  

	18.	S&P High Technology Stock Price Index 

  

	19.	Standard & Poor’s High Technology Stock Price Index 

  

	20.	S&P Public Utility Stock Price Index 

  

	21.	Standard & Poor’s Public Utility Stock Price Index 

  

	22.	S&P Consumer Staple Stock Price Index 

  

	23.	Standard & Poor’s Consumer Staple Stock Price Index 

  

	24.	S&P Transportation Stock Index 

  

	25.	Standard & Poor’s Transportation Stock Price Index 

  

	26.	S&P Euro Index 

  

	27.	S&P Euro Plus Index 

  

	28.	S&P / TOPIX 150 Index 

  

	29.	S&P 500 GICS Sector Indices 

  

	30.	SPDR 

  

	31.	Standard & Poor’s Depositary Receipts 

  

	32.	S&P Asia 50 

  

 Page 30 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 APPENDIX 3 
  
 Prior license agreements and amendments between S&P and CME are the following: 
  

	1.	The 1997 Agreement and the “Prior License Agreements” listed in Appendix 3 to the 1997 Agreement that the 1997 Agreement superseded. 

  

	2.	S&P Euro index and S&P Euro Plus index amendment dated March 2, 1999 

  

	3.	Calculation and disseminations of indices amendment dated April 14, 1999 

  

	4.	MEFF sublicense amendment dated July 27, 1999 

  

	5.	S&P E-mini MidCap 400 Index amendment dated December 26, 2001 

  

	6.	S&P/TOPIX 150 Index amendment dated January 17, 2002 

  

	7.	S&P 500 GICS sectors amendment dated April 22, 2002 

  

	8.	Market data dissemination letter dated April 22, 2002 

  

	9.	S&P Asia 50 Index amendment dated July 8, 2004 

  

	10.	Letter Amendment re: S&P contact information dated November 12, 2004. 

  

	11.	ETF futures amendment dated February 18, 2005. 

  

	12.	CME-S&P Index License Agreement to Amend dated September 20, 2005. 

  

 Page 31 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 APPENDIX 4 
  

			
	Limitation of Standard & Poor’s Liability
		
	 Rule         .
	  	Standard & Poor’s, a division of The McGraw-Hill Companies, Inc. (“S&P”), licenses the Exchange to use various S&P stock indices (“S&P Stock Indices”)
in connection with the trading of futures contracts and options on futures contracts based upon such indices. S&P shall have no liability for any damages, claims, losses or expenses caused by any errors or delays in calculating or disseminating
the S&P Stock Indices.
	
	S&P Disclaimer
		
	 Rule         .
	  	Standard & Poor’s, a division of The McGraw-Hill Companies, Inc. (“S&P”), does not guarantee the accuracy and/or completeness of the S&P Stock Indices or any data
included therein. S&P makes no warranty, express or implied, as to the results to be obtained by any person or any entity from the use of the S&P Stock Indices or any data included therein in connection with the trading of futures contracts,
options on futures contracts or any other use. S&P makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to the S&P Stock Indices or any data
included therein. Without limiting any of the foregoing, in no event shall S&P have any liability for any special, punitive, indirect, or consequential damages (including lost profits), even if notified of the possibility of such
damages.
	
	S&P ETF Contracts Disclaimer
		
	 Rule         .
	  	Standard & Poor’s, a division of The McGraw-Hill Companies, Inc. (“S&P”), does not guarantee the accuracy and/or completeness of the S&P Stock Indices or any data
included therein. S&P makes no warranty, express or implied, as to the results to be obtained by any person or any entity from the use of the S&P Index ETFs or any data included therein in connection with the trading of futures contracts,
options on futures contracts or any other use. S&P makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to the S&P Index ETFs or any data
included therein. Without limiting any of the foregoing, in no event shall S&P have any liability for any special, punitive, indirect, or consequential damages (including lost profits), even if notified of the possibility of such
damages.

  

 Page 32 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 APPENDIX 5 
  
 Calculation Methodology Example 
  
 Initial Conditions: 
  

			
	 1/1/00:
	  	S&P 500 contract multiplier of $***** reduced to $***** (i.e. by a factor of *****);
	 1/1/95-1/1/00:
	  	Average ***** volume of ***** contracts traded;
	 1/1/00-1/1/01:
	  	License fee of $***** based on actual volume and adjusted rate (i.e. *****).
	 1/1/01-1/1/02:
	  	License fee of $***** based on actual volume and adjusted rate (i.e. *****).
	 1/1/02-1/1/03:
	  	License fee of $***** based on actual volume and adjusted rate (i.e. *****).

  

	1.	On January 1, 2000, upon reduction in the S&P 500 contract multiplier, the per-trade license fee paid on the S&P 500 contract is proportionately reduced.

  
 ***** 
  

	2.	On January 1, 2001, multiply the average ***** volume in the S&P 500 contract for the ***** prior to the reduction in the S&P 500 contract multiplier by the
unadjusted license fee in the S&P 500 Contract. 

  
 ***** 
  

	3.	On January 1, 2001, and ***** thereafter, the total license fee paid to S&P by CME in regard to the S&P 500 contract for the ***** is calculated. *****.

  

	4.	CME pays S&P the *****. 

  
 ***** 
  
 ***** 
  
 *****. 
  

	5.	Repeat steps 3 and 4 every ***** for the remainder of the term of the Agreement. 

  

	6.	The adjustment made to S&P is capped at a per-trade rate of $*****. 

  

 Page 33 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 APPENDIX 6 
  
 Calculation Methodology Example 
  
 Initial Conditions: 
  

			
	 1/1/00
	  	CME launches Competitive Contract
	 1/1/95-1/1/00:
	  	Average ***** volume of ***** S&P Affected Contracts traded;
	 1/1/96-1/1/01:
	  	Average ***** volume of ***** S&P Affected Contracts traded;
	 1/1/00-1/1/01:
	  	***** Volumes:
	 	  	 S&P Affected Contract = *****;

	 	  	 Competitive Contract = *****;

	 1/1/01-1/1/02:
	  	***** Volumes:
	 	  	 S&P Affected Contract = *****;

	 	  	 Competitive Contract = *****;

  
 1. The average *****
volume for the S&P Affected Contract in the rolling ***** period minus the volume for the S&P Affected Contract in the ***** period immediately following the rolling ***** period (“Volume Shortfall”). If Volume Shortfall is less
than 0, then, for the purposes of this calculation, Volume Shortfall shall equal 0. 
  
 Year 1 Volume Shortfall = *****; 
  
 Year 2 Volume Shortfall = *****. 
  
 2. Multiply Volume
Shortfall by the average per Contract license fee paid to S&P by CME for the S&P Affected Contract during the ***** preceding the time of calculation (“S&P Revenue Shortfall”). 
  
 Year 1 S&P Revenue Shortfall = ***** 
  
 Year 2 S&P Revenue Shortfall = ***** 
  
 3. The total Normalized Volume is calculated by the following five
(5) steps: 
  
 ***** 
  
 (a) The Normalization Factor is calculated: 
  
 ***** 
  
 ***** 
  
 (b) Normalized Volume is calculated: 
  
 Year 1: ***** 
  
 Year 2: ***** 
  

 Page 34 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 (c) Repeat steps (a) and (b) for each Competitive Contract as it relates to the S&P
Affected Contract. 
  
 (d) Sum the Normalized Volumes for all
Competitive Contracts as they relate to the S&P Affected Contract. 
  
 Year 1: ***** 
  
 Year 2: ***** 
  
 (e) Multiply the sum from step (d) by the per-trade license fee paid for
the S&P Affected Contract at the time this calculation is being performed. (“Total Normalized Revenue”). 
  
 Year 1: ***** 
  
 Year 2: ***** 
  
 The payment to S&P for the ***** period in question is the *****. 
  
 Year 1: ***** 
  
 Year 2: ***** 
  

 Page 35 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 APPENDIX 7 
  
 1. S&P Stock Index Fees. Third party communications vendors that are not existing S&P Vendors (as defined
below) and that wish to obtain from CME the right to display the S&P Stock Indices via a publicly available Internet website or a private network or intranet website (“Communications Vendors”) shall be required to pay the following
fees (“Stock Index Fees”). 
  
 (a) Any
Communications Vendor that wishes to display the S&P Stock Indices on a website that provides access to the S&P Stock Indices only to certain authorized users (i.e., users whose access to the website is conditioned on use of an assigned
password, user identification number or similar identifying information) will be required to pay monthly Stock Index Fees, based on the number of authorized users permitted to access the S&P Stock Indices during that month and whether the
Communications Vendor distributes real-time S&P Stock Indices or delayed (i.e., non-real-time) S&P Stock Indices. CME shall invoice these Communications Vendors on a quarterly basis. 
  

			
	 Real-Time S&P Stock Indices        

	  	 Monthly Stock Index Fee

		
	 *****
	  	 *****

		
	 *****
	  	 *****

		
	 *****
	  	 *****

		
	 Delayed S&P Stock Indices
	  	 
		
	 *****
	  	 *****

		
	 *****
	  	 *****

		
	 *****
	  	 *****

	 Real-Time and Delayed S&P Stock Indices
	  	 *****

  
 (b)
Any Communications Vendor that wishes to display the S&P Stock Indices on a publicly available website (i.e., where use of the website is not conditioned on use of an assigned password, user identification or similar identifying information),
will be required to pay the following annual Stock Index Fees, which vary based on (i) the number of uniform resource locators (“URLs”) on which the S&P Stock Indices will be displayed, (ii) whether the Communications Vendor
receives the S&P Stock Indices directly from CME (“CME Data Vendor”) or via a CME Data Vendor (“Third Party Data Vendor”), and (iii) whether the Communications Vendor distributes real-time S&P Stock Indices or
delayed S&P Stock Indices. These fees include the right to display up to, but not more than, four S&P Stock Indices per URL. Any Communications Vendor that wishes to display more than four S&P Stock Indices on a URL will be required to
pay an additional fee determined by S&P after reasonable consultation with CME in accordance with Section 6 below. CME will invoice these Communications Vendors on an annual basis. 
  

					
	 	  	Real-Time Distributor

	 	Delayed Distributor

	 CME Data Vendor
	  	*****	 	*****
	 Third Party Data Vendor
	  	*****	 	*****

  
 2. Separate S&P
Stock Index Distribution. Any Communications Vendor that wishes to display only the S&P Stock Indices, and not any other CME-distributed data, will be 

  

 Page 36 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 
required to pay $***** per year in addition to any applicable Stock Index Fees under Section 1(a) or 1(b) of this Appendix 7. If such Communications
Vendor subsequently subscribes to other CME-distributed data, CME will issue a credit to that Communications Vendor equal to a pro-rated portion of the $*****, based on the number of months remaining in the year for which the $***** fee was paid.
This credit will be applied against applicable CME data fees. 
  
 3. Revenue Sharing. Except as set forth below, the parties agree that they will share the Stock Index Fees collected by CME from Communications Vendors, such that ***** of the collected Stock Index Fees will be remitted by CME to
S&P (“S&P Share”) and ***** will be retained by CME (“CME Share”). Within 60 days following the end of each three-month period following the April 22, 2002 (a “Quarter”), CME will determine the total
collected Stock Index Fees during that Quarter and will remit to S&P the S&P Share. If at the end of the first twelve-month period following April 22, 2002 or any anniversary thereof, the dollar value of the total S&P Share for that
twelve-month period is less than ***** (the “Minimum Annual S&P Share”), CME shall pay to S&P an amount equal to the difference between the dollar value of the total S&P Share for that twelve-month period and the Minimum Annual
S&P Share. 
  
 4. Existing S&P Vendors. The parties
acknowledge that prior to and subsequent to April 22, 2002, S&P has entered, and/or may enter, into agreements directly with various third party communications vendors in connection with their display of some or all of the S&P Stock
Indices (“S&P Vendors”). CME shall not have the right to receive any portion of the fees S&P collects directly from the S&P Vendors for as long as S&P maintains its own contractual relationship with them in connection with
the S&P Stock Indices. 
  
 5. Additional CME
Responsibilities. 
  
 (a) CME will require
Communications Vendors to sign a contract in a form substantially similar to one of the Vendor Agreements used by CME on or about April 22, 2002. 
  
 (b) CME will submit to S&P on a quarterly basis a report indicating the Communications Vendors to which CME has disseminated the
S&P Stock Indices, the corresponding number of Internet websites on which the S&P Stock Indices are being displayed or, if applicable, the number of authorized users permitted to access the S&P Stock Indices, and payment and account
balance information. 
  
 (c) CME shall employ
commercially reasonable efforts to collect from Communications Vendors the Stock Index Fees that are specified in each invoice. 
  
 6. Additional S&P Responsibilities. S&P may modify the Stock Index Fees at any time by providing to CME at least 90 days’ prior
written notice. S&P agrees that it will consult with CME prior to decreasing the Stock Index Fees; provided, however, that (i) in no event during the term of this Agreement may the Stock Index Fees charged by S&P to any Communications
Vendor or S&P Vendor be less than the Stock Index Fees payable by Communications Vendors that receive the S&P Stock Indices through CME and (ii) if in the future S&P enters into an agreement with a third party redistributor that
provides for S&P to receive a lower percentage of the Stock Index Fees than is set forth under Section 3 of this Agreement, S&P shall immediately so notify CME in writing and the percentage of Stock Index Fees payable by CME to S&P
hereunder shall immediately be reduced to equal such lower percentage. 
  

 Page 37

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}]]